[41] Aaberg KM, Eriksson AS, Ramm-Pettersen J, Nakken KO.
Long-term outcome of resective epilepsy surgery in
Norwegian children. Acta Paediatr. 2012; 101(12):e557–e560
[42] Kayyali HR, Abdelmoity A, Baeesa S. The role of epilepsy
surgery in the treatment of childhood epileptic
encephalopathy. Epilepsy Res Treat. 2013; 2013:983049
[43] Ansari SF, Maher CO, Tubbs RS, Terry CL, Cohen-Gadol AA.
Surgery for extratemporal nonlesional epilepsy in children: a
meta-analysis. Childs Nerv Syst. 2010; 26(7):945–951
[44] Moosa AN, Gupta A, Jehi L, et al. Longitudinal seizure
outcome and prognostic predictors after hemispherectomy
in 170 children. Neurology. 2013; 80(3):253–260
[45] Moosa AN, Jehi L, Marashly A, et al. Long-term functional
outcomes and their predictors after hemispherectomy in 115
children. Epilepsia. 2013; 54(10):1771–1779
[46] Schramm J, Kuczaty S, Sassen R, Elger CE, von Lehe M.
Pediatric functional hemispherectomy: outcome in 92
patients. Acta Neurochir (Wien). 2012; 154(11):2017–2028
[47] Villarejo-Ortega F, García-Fernández M, Fournier-Del Castillo
C, et al. Seizure and developmental outcomes after
hemispherectomy in children and adolescents with
intractable epilepsy. Childs Nerv Syst. 2013; 29(3):475–488
[48] Bower RS, Wirrell E, Nwojo M, Wetjen NM, Marsh WR, Meyer
FB. Seizure outcomes after corpus callosotomy for drop
attacks. Neurosurgery. 2013;73(6):993 – 1000
[49] Iwasaki M, Uematsu M, Sato Y, et al. Complete remission of
seizures after corpus callosotomy. J Neurosurg Pediatr. 2012;
10(1):7–13
[50] Hauptman JS, Mathern GW. Vagal nerve stimulation for
pharmacoresistant epilepsy in children. Surg Neurol Int.
2012; 3 suppl 4:S269–S274
[51] Rolston JD, Englot DJ, Wang DD, Shih T, Chang EF.
Comparison of seizure control outcomes and the safety of
vagus nerve, thalamic deep brain, and responsive
neurostimulation: evidence from randomized controlled
trials. Neurosurg Focus. 2012; 32(3):E14
[52] Susheela SP, Revannasiddaiah S, Mallarajapatna GJ,
Basavalingaiah A. Robotic-arm stereotactic radiosurgery as a
definitive treatment for gelastic epilepsy associated with
hypothalamic hamartoma. BMJ Case Rep. 2013; 2013:2013
Surgical Management of Childhood Epilepsy: Temporal and Extratemporal Pathologies
357
46 Surgical Management of Childhood Epilepsy:
Corpus Callosotomy and Vagal Nerve Stimulation
Oguz Cataltepe
46.1 Introduction
Resective surgical procedures in epilepsy fre-
quently provide seizure-free outcome and they are
accepted as best surgical option for patients with
epilepsy. However, resective surgery may not pro-
vide satisfactory seizure control in many patients.
More significantly, resective surgery may not be
feasible or preferable because of the location,
extent, or multifocality of the epileptogenic focus.
Resective surgical procedures are even not consid-
ered as an option in some cases such as atonic or
multifocal, nonlocalizable seizures. Palliative epi-
lepsy surgery techniques play significant role in
the management of these patients. Although, pal-
liative surgical interventions may not provide seiz-
ure-free outcome, they may still help the patient
to have a better seizure control and improved
quality of life. Corpus callosotomy (CC) and vagal
nerve stimulation (VNS) are two most commonly
used palliative epilepsy surgery interventions and
we will review these techniques here.
46.2 Corpus Callosotomy
Corpus callosum is the largest and most critical
commissure in propagation and generalization of
the epileptogenic discharges to the contralateral
hemisphere. Bilateral synchronization of epilepti-
form discharges, which is critical for generalization
of seizures, also occurs primarily via corpus cal-
losum. These anatomophysiological characteristics
of corpus callosum makes it a very attractive surgi-
cal target to prevent atonic and secondarily gener-
alized seizures and it is one of the oldest epilepsy
surgery procedures.
46.2.1 History
Corpus callosotomy is used in treatment of intract-
able epilepsy first time by Van Wagenen and
Herren in 1940.1 Then Bogen et al published their
corpus callosotomy series in 1960s, and Luessen-
hop et al and Wilson et al reported their experien-
ces in several articles in 1970s.2,3,4,5 Wilson et al
have many contributions to this technique includ-
ing introducing operating microscope to this pro-
cedure.4,5 Surgical technique that was used initially
included division of not only corpus callosum but
also hippocampal and anterior commissures. Then,
Wilson modified this technique in mid-70 s and
started not to divide anterior commissure and for-
nix and to leave the ependymal lining intact to
avoid related complications. Then, he further
modified his technique by applying two-stage sec-
tioning of the corpus callosum with a few months
interval.4,5 Gradually, two-thirds anterior callosot-
omy became a standard CC technique and com-
plete callosotomy was performed only if seizure
control with two-thirds anterior callosotomy is
not satisfactory. Although the early series had high
morbidity and mortality rates, CC gradually
became a safe, e ective, and well-established pro-
cedure with the introduction and refinement of
modern microsurgical techniques.6,7,8,9,10 However,
the number of CC surgeries dramatically decreased
during the following decades in parallel to increas-
ing popularity of vagal nerve stimulator placement
procedures.
46.2.2 Anatomy and Physiology
Corpus callosum is the largest commissure and
principal anatomical and neurophysiological con-
nection pathway between the two hemispheres
and consists of 180 to 200 million axons. Although
it mostly links homotopic areas together, it also
connects heterotopic areas.7,11,12 Corpus callosum
is frequently divided into four sections: rostrum,
genu, body, and splenium. Anterior half of cal-
losum (rostrum, genu, and anterior half of the
body) includes decussation fibers from premotor,
motor, anterior insular, and anterior cingulate
cortical areas. Anterior half of corpus callosum is
essential for the generalization of tonic, tonic–
clonic seizures, and atonic drop attacks. The poste-
rior half of the callosum includes posterior half of
callosal body and splenium. Its fibers connect pari-
etal, occipital, posterior insular, primary auditory
area, and caudal portions of parahippocampus.
46.2.3 Surgical Indications
Corpus callosotomy is considered as a treatment
option for patients with medically intractable gen-
eralized (primary or secondary) seizures that may
358
frequently cause serious injuries secondary to drop
attacks. Lennox–Gastaut is the most responsive
epilepsy syndrome to callosotomy. The patients
with atonic seizures, infantile spasms, unclear-
onset epileptogenic abnormality with secondary
widespread generalization, di use cortical malfor-
mations with generalized seizures might also be
good candidates for CC.9,13,14,15,16 CC may also have
a diagnostic utility to define the seizure focus in
patients with rapid generalization of epileptogenic
activity.17 In these patients, CC may be helpful to
determine the focus of ictal onset by isolating the
hemispheres and providing an opportunity for fur-
ther diagnostic work-up to find a focus, which may
be amenable for resective surgery.
46.2.4 Preoperative Assessment
Preoperative assessment of these patients is simi-
lar to other epilepsy surgery patients. First goal
during the assessment of the patient is ruling out
any lateralizable and localizable epileptogenic
abnormality with a complete investigative work-
up including brain magnetic resonance imaging
(MRI), MR venography, video/electroencephalog-
raphy (EEG) monitoring, and neuropsychological
assessment. Video/EEG monitoring would provide
a critical information regarding seizure semiology
and electrophysiological characteristics of epilep-
togenic abnormalities. MRI is helpful to assess the
structural abnormalities and MR venogram pro-
vides significant information for surgical planning
of CC by showing location and distribution of para-
sagittal veins. Neuropsychological assessment is
especially significant in these cases because pres-
ence of mixed cerebral dominance in complete CC
cases may cause significant postoperative language
deficits.
46.2.5 Surgical Technique
CC procedure has been generally performed as
anterior two-thirds CC. Complete callosotomy is
performed as a second step only if the patient does
not benefit from the initial procedure.
The patient is placed in supine position and the
head is secured with a pin head holder. Right-
sided approach is used unless the patient has a
pathology on the left hemisphere or has a right
hemispheric dominance. The neck is flexed 20
degrees and is slightly tilted to right to use gravity
for retraction during the procedure. A 6-cm length,
lazy-S incision is marked 2 cm anterior and parallel
to the coronal sutures. The incision crosses the
midline to the left side about 2 cm. Two burr holes,
2 cm anterior and 3 cm posterior to coronal suture,
are placed over the sagittal sinus and one burr hole
is placed over the coronal suture about 4 cm lateral
to midline. A triangular-shaped craniotomy flap is
removed. Right-sided edge of the sagittal sinus is
exposed and covered with Surgifoam and cotto-
noids. Dura is tented through the drill holes on
surrounding bone edges. Intravenous mannitol can
be administered at this point if needed. We do not
use lumbar drain in these cases. Then the dura is
opened U-shape and reflected over the sagittal
sinus. MR venogram is reviewed carefully before
surgery to determine the location of large bridging
veins and/or dural venous lacuna. If there are large
draining veins or venous lacuna, dural opening is
made accordingly by leaving dural patches on
them to work around these structures. Arachnoid
granulations are gently dissected from the dura
and sagittal sinus wall, then dural flap is further
retracted, and interhemispheric fissure as well as
falx are exposed. Cottonoid pledgets are placed
over the exposed cortex. At this stage, surgical
microscope is brought into the field and the
remaining part of the surgery is continued under
the microscope. If there are major bridging veins
entering to the sagittal sinus, their arachnoid
sleeves can be dissected as far lateral as possible to
minimize their stretch during the retraction and
surgical procedure can be carried out around these
veins using separate surgical corridors anterior
and posterior to them. However, if the bridging
veins are well anterior to coronal suture and not
draining from eloquent cortex, then they can be
sacrificed if needed. Then the cortex is gently
retracted away from the falx using a single retrac-
tor blade on the mesial frontal cortex. Arachnoid
adhesions extending from cortex to sagittal sinus
or falx can be easily dissected with bipolar and
microscissors while sliding the retractor blade
down. The inferior edge of the falx can also be seen
at this stage. Then the retractor blade is gently
slided further downward along a cottonoid until
cingulate gyrus is seen. At this stage, arachnoid
membrane over the mesial frontal cortex in inter-
hemispheric fissure may be opened at a few
separate points using a fine bipolar forceps and
cerebrospinal fluid (CSF) is drained by suctioning
it through the cotton balls. This maneuver pro-
vides a much relaxed exposure and the retractor
can be removed at this stage and only used as
needed to avoid unnecessary pressure over the
cortex. Then dissection is further advanced down-
ward to fully expose the cingulate gyri. Separation
Surgical Management of Childhood Epilepsy: Corpus Callosotomy and Vagal Nerve Stimulation
359
of cingulate gyri from each other can be di cult in
some cases because of arachnoid adhesions and
interdigitation of gyri. After finding a relatively
free part, dissection of the cingulate gyri can be
performed easily using bipolar forceps and Pen-
field # 4 dissector. At this point, underlying glisten-
ing white corpus callosum is encountered with a
very distinctive appearance and consistency. Next,
the cortical ribbon is repositioned and further CSF
drainage is obtained through supracallosal cistern.
Then, flu y small cotton balls are placed down-
ward just over corpus callosum at both ends of the
exposed area to keep cingulate gyri separated and
to expose corpus callosum better. At this stage,
pericallosal arteries are also seen. They frequently
travel very close to each other with some tiny
bridging vessels and sometimes they may even
override. Then pericallosal arteries are mobilized
and separated to have a wider exposure of the cor-
pus callosum. This will provide a satisfactory expo-
sure for performing planned CC. Corpus callosum
division should be done between pericallosal
arteries by staying strictly on the midline. Dividing
corpus callosum lateral to pericallosal artery may
cause injury to perforating vascular structures in
the pericallosal sulcus and cause ischemic damage
and edema. Corpus callosum is divided longitudi-
nally using microdissectors and bipolar forceps.
When the division of corpus callosum is deepened,
a grayish color of the ependymal lining can be
easily appreciated. Opening the ependyma and
entering into ventricle should be avoided if possi-
ble to decrease the risk of chemical meningitis. CC
is continued anteriorly around the genu until the
visualization of anterior commissure between the
fornices. Anterior commissure should be left intact.
Then dissection continues posteriorly on the ros-
trum and anterior body of the corpus callosum.
Posterior end of the callosotomy is determined
based on surgical planning. If anterior two-thirds
is aimed, then the length can be measured preop-
eratively using midsagittal MRI images. The meas-
urement is translated onto the surgical field using
a ruler or by using the thickness of the ribbon as
measuring tool. Another practical and more reli-
able tool to use for this purpose is neuronavigator.
After completing callosotomy as planned, meticu-
lous hemostasis is obtained and the layers are
closed appropriately.
If the goal is performing posterior callosotomy
or completing the anterior two-thirds craniotomy
to a complete callosotomy, a second incision, par-
allel to the first one, is placed at vertex level. The
incision crosses the midline 2 cm to the left and
the surgical field is exposed with self-retaining
retractors. Targeted exposed area in midline
extends from 4 cm anterior to lambda to just over
or 1 cm behind the lambda posteriorly. The burr
holes in midline are placed on sagittal sinus and
the lateral burr hole is placed 4 cm lateral to mid-
line on the right to remove a free bone flap. Using
the same surgical technique described above, the
dura is opened and the dissection is continued
toward the posterior body of the callosum and
splenium by following falx. It is very critical to stay
on midline during this part of the procedure to
avoid any injury to fornices. Neuronavigator would
be very helpful in these cases. The division of the
corpus callosum ends with the exposure of the
arachnoid membranes covering the vein of Galen.
46.2.6 Surgical Complications
and Side E ects
Complication rates for CC procedure have been
reported 3 to 10% in di erent series. Most com-
mon complications are cerebral edema, infarction,
meningitis (septic/aseptic), hydrocephalus, ische-
mia, and subdural/epidural hematoma originating
from parasagittal veins.8,9,18,19 Another well-know,
although rare, issue is disconnection-related syn-
dromes. This is closely related to the extent of cal-
losotomy. Anterior two-thirds callosotomy may
cause decreased spontaneity of speech that gener-
ally persists between a few days or weeks. In some
cases, left-sided neglect, apraxia, various degrees
of left leg paresis, hemiparesis, left-sided or bilat-
eral forced grasp reflexes, bilateral extensor plan-
tar responses, and urgency incontinence may be
also seen.8,9,18 Symptoms typically improve over
days to weeks. Surgical retraction-related brain
edema on nondominant parasagittal cortex, sup-
plementary motor area, or premotor cortex might
be responsible from these findings.
On the other hand, posterior callosotomy causes
interhemispheric somatosensory, auditory, and
visual disconnection syndromes, which are fre-
quently temporary. However, permanent interhe-
mispheric sensory disconnection can also develop
and especially sectioning of splenium can result in
visual and sensory disconnection syndromes with
inability to describe the objects presented visually
or tactilely on the nondominant side.6,7,13,18
Complete corpus callosotomy–related side
e ects include both anterior and posterior callos-
otomy–related findings which are described above.
It may also infrequently cause interhemispheric
Functional Disorders
360
antagonism. Split-brain syndrome can develop
after complete callosotomy which involves lan-
guage impairment, hemisphere competition, and
disordered attention-memory sequencing. These
findings generally improve with time.7
46.2.7 Outcome
One of the largest reviews on corpus callosotomy
included 563 patients from multiple centers.20 This
study reported that 60.9% of the patients had
worthwhile improvement with rare seizures, 7.6%
of the patients had seizure-free outcome, and
31.4% had no improvement. Some other large ser-
ies also provided similar results.18,21
The outcome of the corpus callosotomy has also
been reviewed based on the extent of callosot-
omy.8,10,17,22,23 Spencer et al reported better out-
come with complete corpus callosotomy than
partial callosotomy (80 vs. 50% satisfactory
improvement).21 Roberts and Siegel reported these
rates as 81 and 38% in their series.8 Some other
authors also reported better outcome with com-
plete corpus callosotomy in comparison to partial
corpus callosotomy.10,19,23,24,25,26,27,28 On the other
hand, Jea et al reported that children in both ante-
rior two-thirds and complete callosotomy groups
achieved comparable improved seizure control, 80
and 87.5%, respectively.16 Again, Fuiks et al did not
find any significant di erence between the two
approaches.22 Tanriverdi et al reported a large
series that includes 95 patients and stated that
complete callosotomy was not necessary at least
initially and it should be reserved as a second stage
in those cases in which anterior two-thirds resec-
tion fails.29
Outcome assessments based on seizure type
were reported in several series. Roberts and Siegel
published a detailed outcome analysis based on
the seizure types.8 They reported that atonic seiz-
ures responded best to corpus callosotomy with
72% significant improvement rate, 21% of them
being seizure free. These authors observed 34%
seizure freedom and 24% significant improvement
(> 50% reduction in seizure frequency) in patients
with generalized major motor seizures and 42%
seizure freedom and 20% significant improve-
ments in patients with complex partial seizures.
The worst outcome was seen in the focal motor
seizure group. According to Pinard et al, the best
outcomes were associated with drop attacks with
dramatical reduction in frequency in 90% of the
children.10 In another series, Kawai et al reported
complete resolution of drop attacks in 80% of their
patients.14 In Tanriverdi et al series, the best res-
ponse was achieved in generalized tonic–clonic
seizures (77.3%), followed by drop attacks (77.2%),
and generalized tonic seizures and simple partial
seizures (71.4%).29
Overall, best response to corpus callosotomy is
seen in patients with generalized tonic–clonic
seizures with drop attacks, and patients with com-
plex partial seizures with or without secondary
generalization. Atypical absence seizures consti-
tute the worst outcome group.15,29
46.3 Vagal Nerve Stımulatıon
VNS therapy has been used in the treatment of
refractory epilepsy since 1988. Its e ectivity and
safety profile extensively tested since then and its
e ciency is consistently demonstrated in many
trials and series. Currently, VNS is one of the most
commonly used adjunctive treatment modalities
in epilepsy.
46.3.1 History
First study on the e ect of VNS on cerebral activity
was performed by Bailey and Bremer in 1938 in an
animal model.30 They demonstrated VNS-related
changes in cortical EEG patterns using various ani-
mal models. Then in 1952, Zanchetti used a chemi-
cally induced seizure model in cats to demonstrate
reduction in interictal epileptic activities by
intermittent stimulation of vagal nerve.31 Several
decades later, Zabara conducted a series of animal
studies to assess the e ect of VNS on seizure con-
trol and published his findings in 1985.32 Then,
Zabara and Reese developed first vagal nerve stim-
ulator model and then, first VNS implantation pro-
cedure in a patient was performed by Bell and
Penry in 1988.33,34 This was followed by a series of
pilot studies with VNS Therapy System (Cyberonics
Inc., Houston, Texas). VNS Study Group conducted
five multicenter VNS clinical trials, the final one
being in 1996, and published their results in a
series of articles.33,35,36,37
European community
approved VNS therapy for epilepsy in 1994 and
Food and Drug Administration (FDA) approved it in
1997.33 Finally, American Academy of Neurology’s
Therapeutics and Technology Assessment Subcom-
mittee reported that “su cient evidence exists to
rank VNS for epilepsy as e ective and safe, based
on a preponderance of Class I evidence.”38,39
Surgical Management of Childhood Epilepsy: Corpus Callosotomy and Vagal Nerve Stimulation
361
46.3.2 Vagus Nerve Anatomy
Vagus nerve is a mixed cranial nerve with both
a erent and e erent fibers. A erent fibers consti-
tute approximately 80% of the vagus nerve which
is composed of myelinated A, B, and nonmyeli-
nated C fibers. Vagus nerve receives somatic sen-
sory, visceral sensory, and special sensory a erent
fibers and reaches to many parts of the brain with
extensive projection fibers. Nucleus tractus solitar-
ius (NTS) is the main recipient of the majority of
a erent sensory fibers. Di use pathways originat-
ing from NTS are connected to dorsal raphe, locus
coeruleus, the nucleus ambiguous, and reaches with
extensive projection fibers to wide areas in the brain
including cerebellum, hypothalamus, thalamus, and
limbic structures. This anatomical and physiological
characteristic of vagus nerve makes it a perfect
pathway for neuromodulation.40,41
46.3.3 Mechanism of Action
Precise mechanism of seizure suppression of VNS
therapy is still not completely understood. It was
demonstrated that vagal nerve projections extend
noradrenergic and serotonergic neuromodulatory
systems of the brain via NTS through locus coeru-
leus and raphe nuclei. Some studies using animal
models documented that activation of noradrener-
gic and serotonergic neurons has antiepileptic
e ects. It has also been demonstrated that VNS sti-
mulation increases neuronal c-fos protein expres-
sion, increases regional blood flow in some areas
such as thalamus, putamen, and cerebellum and
again causes local or regional increase in GABA
levels and decrease in glutamate aspartate lev-
els.40,41,42,43,44,45 Therefore, it is possible that action
of VNS might be related to noradrenergic and sero-
tonergic neuromodulatory systems, modulation of
excitatory and inhibitory neurotransmitters, and
also possibly by modified cerebral electrical activ-
ity through thalamocortical pathways.
46.3.4 Safety and E ectiveness
Series of large multicenter studies are conducted
and many series are published to assess the safety
and e ectiveness of VNS since the first pilot study
in 1998.45,46,47,48,49,50,51,52,53 VNS Study Group con-
ducted three open-label and two double-blind
randomized controlled trials and results were
published separately and also as a meta-analysis of
five studies.35,36,37,38,39
It was reported that
although only 1 to 2% of patients became seizure
free, many patients had significant long-term ben-
efit from VNS with an average 50% seizure reduc-
tion in 43% of patients at 3 years after VNS
placement. Although, there is no prospective,
randomized controlled trial in pediatric age group,
many pediatric series also consistently demon-
strated sustained, long-term improvement in
seizure control and quality of life after VNS place-
ment.46,50,51,52,53
46.3.5 VNS Therapy System
Components
The VNS Therapy System (Cyberonics Inc.,
Houston, Texas) composed of an implantable, pro-
grammable pulse generator and a bipolar lead.
Nonimplantable components of the system are a
programming wand and a handheld computer
with software. The pulse generator delivers a
biphasic current to the vagal nerve through the
bipolar lead with cycles between on and o peri-
ods. Current generators are model 102/102 R 105
and 106 (25 g, 6.9-mm thickness) and smaller one,
model 103 (16 g, 6.9-mm thickness) ( Fig. 46.1).
There are two lead sizes (2- and 3-mm helix inner
diameters). VNS lead has three helical (two elec-
trodes and one anchor tether), which are wrapped
around the vagal nerve and an extension cable
ending with a connector pin for insertion into gen-
erator47 ( Fig. 46.2 and Fig. 46.3).
46.3.6 Indications
VNS is used as an adjunctive therapy in patients
with medically refractory epilepsy who are not
candidates for resective epilepsy surgery or who
Fig. 46.1 Various VNS pulse generators: the models
102,103, and 105. (Reproduced with permission from
Cyberonics.)
Functional Disorders
362
have not responded to previous resective surgical
interventions satisfactorily. Its e ectiveness is
demonstrated in generalized epilepsy, Lenox–
Gastaut syndrom e, and partial-onset seizures.38,45,
46,47,48,49,50,53
46.3.7 Preoperative Assessment
The patients have standard epilepsy surgery work-
up. It needs to be demonstrated that patients’ seiz-
ures are medically refractory and no resectable
epileptogenic focus is present. History of cardiac
dysfunction, apnea, and swallowing di culties
should also be questioned because of the possibil-
ity of worsening on these problems with VNS
placement.
46.3.8 Surgery
VNS placement is typically performed under gen-
eral anesthesia. Left vagal nerve is used for VNS
placement because right vagal nerve innervates
sinoatrial node and stimulation of left vagal nerve
is less likely cause any cardiac problem.
The patient is placed in supine position with a
shoulder role under the neck to give some exten-
sion. Head stays in neutral position or slightly
turns to right. Left-sided neck and chest are
prepped and draped as usual sterile manner. Intra-
venous antibiotic is given before skin incision. Sur-
gery is performed under optic magnification. Two
skin incisions on the left side are marked: one over
the neck and the other is on chest. Neck incision is
placed at midpoint of a line between mastoid tip
and medial edge of the clavicula. A transverse,
2- to 3-cm length incision, preferably on a skin
fold, is marked by centering the medial border of
sternocleidomastoid muscle (SCM). Chest incision
is placed on anterior axillary line and the length is
determined based on the generator size. While a
small, 2 cm, incision might be su cient for model
103 generators, a larger incision will be needed for
models 101, 102/102 R. Neck incision is fashioned
first. After skin incision on neck, platysma is
sharply opened and undermined superiorly and
inferiorly. Then cervical fascia is opened along the
medial border of sternocleidomastoid muscle. Dis-
section continues along the medial border of SCM
toward the neurovascular bundle. Carotid pulse is
palpated to guide the dissection. After reaching
the carotid sheath, it is opened sharply parallel to
vascular structures. Internal jugular vein and caro-
tid artery are easily exposed and gently separated
by dissecting bluntly and holding separated with
handheld retractors. Vagus nerve is generally
located between these vessels posteriorly and fre-
quently closer to jugular vein, although variations
on the location of vagus nerve is not uncommon.
Then about 3-cm length segment of vagus nerve is
dissected proximally and distally and a vessel loop
is passed underneath. Then chest incision is fash-
ioned to create an appropriate size subcutaneous
pocket for generator. This pocket is prepared in
subclavicular area at left upper chest by exposing
pectoralis fascia. Then a tunneler was inserted
from chest incision and exited from neck incision.
Lead cable is placed subcutaneously through the
tunneler. Then helical electrodes and anchor tether
are wrapped around vagal nerve one by one. First
anchoring electrode, then positive electrode, and
lastly negative electrode is placed. Anchor helix
should be located farthest away from head and
Fig. 46.3 Configuration of implanted VNS system.
(Reproduced with permission from Cyberonics.)
Fig. 46.2 VNS lead with helical electrodes. (Repro-
duced with permission from Cyberonics.)
Surgical Management of Childhood Epilepsy: Corpus Callosotomy and Vagal Nerve Stimulation
363
other two electrodes should be closer to head. All
three helical electrodes should be coiled around
vagal nerve segment below where the superior
and inferior cardiac branches separate from the
vagus nerve. All electrodes have attached sutures
at the end and all manipulations during electrode
placement should be done by holding these
sutures, but not electrodes itself, with fine forceps.
It is also very significant not to stretch or to devas-
cularize vagus nerve or its branches during coiling
the electrodes. Vagus nerve also should be kept
moist throughout the procedure. After wrapping
all three coils around the vagus nerve, it should be
verified that lead cables exiting from coils are at
the same direction and parallel to each other as
well as to vagus nerve. After wrapping all three
coils around the vagus nerve, coiled nerve is
placed back to its original anatomical location
without any stretch. Then a strain relief loop was
created at the distal end by turning the cable
upward. The lead is secured to deep fascia with a
tie-down and nonabsorbable suture. Then another
strain relief loop is created above the SCM and
again it is secured to fascia with another tie-down.
Then lead connector pin is inserted into pulse
generator and connection is locked down by tight-
ening the set screw with hex screwdriver. First
intraoperative diagnostic testing of the system is
performed at this stage to ensure the system integ-
rity. Then pulse generator is inserted into subcuta-
neous pocket and extra lead is coiled and placed to
the side of the generator. The generator is secured
to pectoralis fascia with a silk suture. Surgical sites
are irrigated with antibiotic-containing saline.
Then all layers, platysma, subcutaneous tissue, and
skin incision are closed with absorbable sutures.
Second intraoperative diagnostic testing is again
performed after skin closure using programming
wand and handheld computer to confirm that the
lead impedance is correct and the generator func-
tions normally.
46.3.9 Surgical Complications
and Side E ects
VNS procedure has relatively low rate of complica-
tions. Complications include infection, hoarseness
of voice, temporary vocal cord paralysis, and,
although much rare, nerve damage, vascular
injury, bradycardia, asystole. Side e ects typically
occur during stimulation and improves over time.
Most common side e ects are voice alteration/
hoarseness, throat paresthesia, cough, shortness of
breath, and less frequently, drooling, and sleep
apnea. Side e ects can be frequently eliminated
with some changes in stimulation parameters such
as reducing the pulse width or signal frequency
even without changes in output current.36,37,38,45,46,
50,51,52,53,54
46.3.10 Postoperative Care
VNS system is generally activated 2 weeks after
implantation to give some time to recover. Initial
setting is typically 0.25-mA output current, 20- to
30-Hz frequency, 250 to 500 microseconds pulse
width, on for 30 seconds, o for 5 minutes. The sti-
mulation setting is readjusted by epileptologist
over the weeks based on the patient’s response
and degree of side e ects. The goal is obtaining
maximum seizure control with minim al side
e ect.
Long-term follow-up is performed in epilepsy
clinic with periodic diagnostic checks to determine
the status of generator. Approximate battery life of
the pulse generator is 5 to 6 years, depending on
set stimulation parameters as well as extent of
magnet use. It is always preferable to replace the
generator before it is depleted.
46.3.11 Precautions
Patients with VNS should not receive shortwave
diathermy or microwave diathermy. Again, thera-
peutic radiation therapy, external defibrillation,
extracorporeal shockwave lithotripsy, or electro-
surgery may damage the pulse generator. MRI
can be performed with certain conditions. It
should not be performed with MRI body coil in
transmitter mode. 1.5 Tesla brain MRI with trans-
mit-and-receive type head coils is considered as a
safe procedure. The patient’s VNS generator output
current should be set to 0 mA before MRI and it
should be tested and reprogrammed to original
setting after MRI. Diagnostic ultrasound is a safe
procedure for patients with VNS.47
46.3.12 Outcome
All published outcome studies regarding VNS in
pediatric age group shows satisfactory benefit on
seizure control.36,37,38,45,46,50,51,52,53,55 Several large
series reported about 50% responder rate with,
again, about 50% decrease in overall seizure fre-
quency. Elliott et al reported 56% seizure reduction
and 64% responder rate in a series of 436
patients.56 These rates were 51 and 59% (n:138
Functional Disorders
364
patients) in De Herdt, 51 and 59% (n: 269 patients)
in Labar, 44% and 43% (n:440 patients) in Morris,
58% and 57% (n: 125 patients) in Helmers et al ser-
ies.37,57,58,59 It has been also consistently demon-
strated in all these studies that response to VNS
therapy improves with tolerance to side e ects
over time and is also sustains long term.
46.3.13 Failure and Removal
When necessary, both generator and lead can be
removed. While generator removal is a simple pro-
cedure, removal of the lead is a challenging proce-
dure with certain risks because of scarring of coil
electrodes to vagus nerve and even to adjacent
vascular structures. If removal of coil electrodes is
not feasible, the lead might be removed by cutting
the lead to leave only coils in place. In that case, no
more than 4 cm of the lead wire should be left
remaining.
46.4 Conclusions
Both corpus callosotomy and VNS therapy are
e ective palliative treatm ent options for patients
w ith m edically refractory epilepsy. Callosotomy
is associated with greater e cacy in patients
w ith drop attacks and Lennox–Gastaut syndro-
m e, but it has higher risk for complications than
VNS. Safety and e ectiveness of VNS therapy
have been confirm ed w ith m any studies includ-
ing several random ized controlled trials and it
has been used w idely both in adult and pediatric
patients. VNS becam e m ost com m only used pal-
liative surgical procedure today. Although VNS
has comparable results in m ost of the cases, cor-
pus callosotomy is still a viable option in the
patients with drop attacks and Lennox–Gastaut
syndrom e and also in patients w ho did not
respond to vagal nerve stim ulator. In general,
VNS is considered as the initial approach in vast
m ajority of cases because of better adverse event
profile than corpus callosotomy which is still the
m ore e cient treatm ent option for drop attacks
and Lennox–Gastaut syndrom e.24,25,26,27
46.5 Common Clinical
Questions
1. What is the most common corpus callosotomy
technique and which parts of the corpus
callosum are divided?
2. Describe the most common complications of
corpus callosotomy.
3. Which patient group responds better to corpus
callosotomy?
4. What is the mechanism of action of VNS
therapy?
5. Describe the most common complications and
side e ects of VNS therapy.
46.6 Answers to Common
Clinical Questions
1. Partial or anterior two-thirds corpus
callosotomy is the most common callosotomy
technique today. Genu, rostrum, and anterior
half of callosal body is divided and posterior
end of the callosal body with splenium is spared
in this technique.
2. Cerebral edema, meningitis (septic/aseptic),
hydrocephalus, ischemia/infarction, subdural/
epidural hematoma, and disconnection
syndromes are most commonly seen
complications of corpus callosotomy
procedures.
3. Patients with generalized tonic–clonic seizures
with drop attacks and Lennox–Gastaut
syndrome respond better to corpus
callosotomy.
4. We do not know the precise mechanism of
action of VNS therapy. However, mechanism of
action of VNS most likely related to
noradrenergic and serotonergic
neuromodulatory systems, modulation of
excitatory and inhibitory neurotransmitters,
and also possibly related to modification of
cerebral electrical activity through
thalamocortical pathways.
5. Voice alteration/hoarseness, throat paresthesia,
cough, shortness of breath, and less frequently,
drooling, and sleep apnea.
References
[1] Van Wagenen WP, Herren RY. Surgical division of the
commissural pathways in the corpus callosum: relation to
spread of an epileptic attack. Arch Neurol Psychiatry. 1940;
44:740–759
[2] Bogen JE, Sperry RW, Vogel PJ. Commissural section and
propagation of seizures. In: Jasper HH, Ward AA, Pope A, eds.
Basic Mechanism of the Epilepsies. Boston, MA: Little Brown
and Company; 1969:439–440
[3] Luessenhop AJ, Dela Cruz TC, Fenichel GM. Surgical
disconnection of the cerebral hemispheres for intractable
seizures. Results in infancy and childhood. JAMA. 1970; 213
(10):1630–1636
Surgical Management of Childhood Epilepsy: Corpus Callosotomy and Vagal Nerve Stimulation
365
[4] Wilson DH, Reeves A, Gazzaniga M. Division of the corpus
callosum for uncontrollable epilepsy. Neurology. 1978; 28
(7):649–653
[5] Wilson DH, Reeves AG, Gazzaniga MS. “Central”
commissurotomy for intractable generalized epilepsy: series
two. Neurology. 1982; 32(7):687–697
[6] Spencer SS, Gates JR, Reeves AR, Spencer DD, Maxwell RE,
Roberts D. Corpus callosum section. In: Engel J Jr, ed. Surgical
Treatment of Epilepsies, New York, NY: Raven press;
1987:425–444
[7] Zentner J. Surgical aspects of corpus callosum section. In:
Tuxhorn I, Holthausen H, Boenigk H, eds. Pediatric Epilepsy
Syndromes and Their Surgical Treatment. London, UK: John
Libbey; 1997;830–849
[8] Roberts D, Siegel A. Section of corpus callosum for epilepsy.
In: Schmideck HH, Sweet WH, eds. Operative Neurosurgical
Techniques. 4th ed. Philadelphia, PA: W. Saunders;
2000:1490–1498
[9] Menezes MS. Indications for corpus callosum section. In:
Miller JW, Silbergerd DL, eds. Epilepsy Surgery: Principles
and Controversies. London, UK: Taylor & Francis; 2006:556–
562
[10] Pinard JM, Delalande O, Chiron C, et al. Callosotomy for
epilepsy after West syndrome. Epilepsia. 1999; 40(12):1727–
1734
[11] Tomasch J. Size, distribution, and number of fibres in the
human corpus callosum. Anat Rec. 1954; 119(1):119–135
[12] Gazzaniga M, Ivry RB, Mangun GR. Cerebral lateralization
and specialization. In: Cognitive Neuroscience: The Biology of
the Mind. 2nd ed. New York, NY: WW Norton; 2002:405–
410
[13] Sass KJ, Novelly RA, Spencer DD, Spencer SS. Postcallosotomy
language impairments in patients with crossed cerebral
dominance. J Neurosurg. 1990; 72(1):85–90
[14] Kawai K, Shimizu H, Yagishita A, Maehara T, Tamagawa K.
Clinical outcomes after corpus callosotomy in patients with
bihemispheric malformations of cortical development. J
Neurosurg. 2004; 101(1) Suppl:7–15
[15] Bower RS, Wirrell E, Nwojo M, Wetjen NM, Marsh WR, Meyer
FB. Seizure outcomes after corpus callosotomy for drop
attacks. Neurosurgery. 2013; 73(6):993–1000
[16] Jea A, Vachhrajani S, Johnson KK, Rutka JT. Corpus
callosotomy in children with intractable epilepsy using
frameless stereotactic neuronavigation: 12-year experience
at the Hospital for Sick Children in Toronto. Neurosurg Focus.
2008; 25(3):E7
[17] Clarke DF, Wheless JW, Chacon MM, et al. Corpus
callosotomy: a palliative therapeutic technique may help
identify resectable epileptogenic foci. Seizure. 2007; 16(6):
545–553
[18] Wong TT, Kwan SY, Chang KP, et al. Corpus callosotomy in
children. Childs Nerv Syst. 2006; 22(8):999–1011
[19] Maehara T, Shimizu H. Surgical outcome of corpus
callosotomy in patients with drop attacks. Epilepsia. 2001;
42(1):67–71
[20] Engel J, Van Ness PJ, Rasmussen TB, Ojemann LM. Outcome
with respect to epileptic seizures. In: Engel J, ed. Surgical
treatment of the epilepsies. 2nd ed. New York, NY: Raven
Press; 1993:609–621
[21] Spencer SS, Spencer DD, Sass K, Westerveld M, Katz A,
Mattson R. Anterior, total, and two-stage corpus callosum
section: di erential and incremental seizure responses.
Epilepsia. 1993; 34(3):561–567
[22] Fuiks KS, Wyler AR, Herm ann BP, Somes G. Seizure outcome
from anterior and complete corpus callosotomy. J Neurosurg.
1991; 74(4):573–578
[23] Rahimi SY, Park YD, Witcher MR, Lee KH, Marrufo M, Lee MR.
Corpus callosotomy for treatment of pediatric epilepsy in the
modern era. Pediatr Neurosurg. 2007; 43(3):202–208
[24] Nei M, O’Connor M, Liporace J, Sperling MR. Refractory
generalized seizures: response to corpus callosotomy and
vagal nerve stimulation. Epilepsia. 2006; 47(1):115–122
[25] You SJ, Kang HC, Ko TS, et al. Comparison of corpus
callosotomy and vagus nerve stimulation in children with
Lennox-Gastaut syndrome. Brain Dev. 2008; 30(3):195–199
[26] Lancman G, Virk M, Shao H, et al. Vagus nerve stim ulation vs.
corpus callosotomy in the treatment of Lennox-Gastaut
syndrome: a meta-analysis. Seizure. 2013; 22(1):3–8
[27] Rosenfeld WE, Roberts DW. Tonic and atonic seizures:
what’s next–VNS or callosotomy? Epilepsia. 2009; 50 Suppl
8:25–30
[28] Jalilian L, Limbrick DD, Steger-May K, Johnston J, Powers AK,
Smyth MD. Complete versus anterior two-thirds corpus
callosotomy in children: analysis of outcome. J Neurosurg
Pediatr. 2010; 6(3):257–266
[29] Tanriverdi T, Olivier A, Poulin N, Andermann F, Dubeau F.
Long-term seizure outcome after corpus callosotomy: a
retrospective analysis of 95 patients. J Neurosurg. 2009; 110
(2):332–342
[30] Bailey P, Bremmer FA. A sensory cortical representation of
vagus nerve with a note on the low pressure in a surface
electrogram. J Neurophysiol. 1938; 1:404–412
[31] Zanchetti A, Wang SC, Moruzzi G. The e ect of vagal a erent
stimulation on the EEG pattern of the cat. Electroencephalogr
Clin Neurophysiol. 1952; 4(3):357–361
[32] Zabara J. Time course of seizure control to brief repetitive
stim uli. Epilepsia. 1985; 26:518
[33] Lulic D, Ahmadian A, Baaj AA, Benbadis SR, Vale FL. Vagus
nerve stimulation. Neurosurg Focus. 2009; 27(3):E5
[34] Penry JK, Dean JC. Prevention of intractable partial seizures
by intermittent vagal stimulation in humans: preliminary
results. Epilepsia. 1990; 31 Suppl 2:S40–S43
[35] Ben-Menachem E, Mann-Espaillat R, Ristanovic R, et al. VNS
for treatment of partial seizures: 1. A controlled study of
e ect on seizures. First International Vagus Nerve
Stimulation Study Group. Epilepsia. 1994; 35:616–626
[36] Handforth A, DeGIorgio CM, Schachter SC, et al. VNS therapy
for partial-onset seizures: a randomized active control trial.
Neurology. 1998; 51:48–55
[37] Morris GL, Mueller WM. Long-term treatm ent with VNS in
patients with refractory epilepsy. VNS Study Group E01–E05.
Neurology. 1999; 53:1731–1735
[38] Schachter SC. Vagus nerve stim ulation therapy summary:
five years after FDA approval. Neurology. 2002; 59(6) Suppl
4:S15–S20
[39] Fisher RS, Handforth A. Reassessment: VNS for epilepsy: a
report of the Therapeutics and Technology Assessment
Subcommittee of the American Academy of Neurology.
Neurology. 1999; 53:666–669
[40] Fanselow EE. Central mechanisms of cranial nerve
stim ulation for epilepsy. Surg Neurol Int. 2012; 3 Suppl 4:
S247–S254
[41] Krahl SE, Clark KB. Vagus nerve stimulation for epilepsy: A
review of central mechanisms. Surg Neurol Int. 2012; 3 Suppl
4:S255–S259
[42] Henry TR. Therapeutic mechanisms of vagus nerve
stim ulation. Neurology. 2002; 59(6) Suppl 4:S3–S14
[43] Naritoku DK, Terry WJ, Helfert RH. Regional induction of fos
immunoreactivity in the brain by anticonvulsant stimulation
of the vagus nerve. Epilepsy Res. 1995; 22(1):53–62
[44] Vonck K, De Herdt V, Bosman T, Dedeurwaerdere S, Van
Laere K, Boon P. Thalamic and limbic involvement in the
Functional Disorders
366
mechanism of action of vagus nerve stimulation, a SPECT
study. Seizure. 2008; 17(8):699–706
[45] Amar AP, Heck CN, Levy ML, et al. An institutional experience
with cervical vagus nerve trunk stim ulation for medically
refractory epilepsy: rationale, technique, and outcome.
Neurosurgery. 1998; 43(6):1265–1276, discussion 1276–
1280
[46] Healy S, Lang J, Te Water Naude J, Gibbon F, Leach P. Vagal
nerve stimulation in children under 12 years old with
medically intractable epilepsy. Childs Nerv Syst. 2013; 29
(11):2095–2099
[47] Cyberonics, Inc. VNS therapy product manuals and safety
alerts. 2013
[48] Labar D, Murphy J, Tecoma E. Vagus nerve stim ulation for
medication-resistant generalized epilepsy. E04 VNS Study
Group. Neurology. 1999; 52(7):1510–1512
[49] Ben Menachem E, Hellstrom K, Runmarker B, Augustinsson
LE. A prospective single-center open-label trial of VNS in 59
patients for the treatment of refractory epilepsy. Epilepsia.
1997; 38 suppl 8:208
[50] Alexopoulos AV, Kotagal P, Loddenkemper T, Hammel J,
Bingaman WE. Long term results with VNS in children with
pharmacoresistant epilepsy. Seizure. 2006; 15:491–503
[51] Benifla M, Rutka JK, Logan W, Donner EJ. VNS for refractory
epilepsy in children: indications and experience in the
Hospital for Sick Children. Childs Nerv Syst. 2006; 22:1018–
1026
[52] Shermann EM, Connolly MB, Slick DJ, Eyrl KL, Steinbok P,
Farrell K. Quality of life and seizure outcome after VNS in
children with intractable epilepsy. J Child Neurol. 2008; 23:
991–998
[53] Elliott RE, Rodgers SD, Bassani EL, et al. VNS for children with
treatment-resistant epilepsy: a consecutive series of 141
cases. J Neurosurg Pediatr. 2011; 7:491–500
[54] Ben-Menachem E. Vagus nerve stimulation, side e ects, and
long-term safety. J Clin Neurophysiol. 2001; 18(5):415–418
[55] Ben-Menachem E. Vagus-nerve stim ulation for the treatment
of epilepsy. Lancet Neurol. 2002; 1(8):477–482
[56] Elliott RE, Morsi A, Kalhorn SP, et al. VNS in 436 consecutive
patients with treatment-resistent epilepsy: long-term
outcome and predictors of response. Epilepsy Behav. 2011;
20:57–63
[57] De Herdt V, Boon P, Ceulemans B, et al. VNS for refractory
epilepsy: a Belgian multicenter study. Eur J Paediatr Neurol.
2007; 11:261–269
[58] Labar D. VNS for 1 year in 269 patients on unchanged
antiepileptic drugs. Seizure. 2004; 13:392–398
[59] Helmers SL, Wheless JW, Frost M, et al. VNS therapy in
pediatric patients with refractory epilepsy: retrospective
study. J Child Neurol. 2001; 16:843–848
Surgical Management of Childhood Epilepsy: Corpus Callosotomy and Vagal Nerve Stimulation
367
47 Surgical Management of Pediatric Spasticity
Michael M. McDowell, Michelle Q. Phan, Richard C.E. Anderson
47.1 Introduction
Spasticity is a condition of hypertonia, causing
hyperactive reflexes, poor coordination, and weak-
ness that can greatly a ect a child’s comfort level
and ability to perform daily activities. Spasticity is
distinguished from other forms of childhood
hypertonia, such as rigidity and dystonia, in that it
is defined as hypertonia with velocity-dependent
resistance to externally imposed movements.1
47.2 Epidemiology and
Pathophysiology
In children, the most common cause of spasticity
and motor disability is cerebral palsy. Cerebral
palsy is not a discrete disorder, but a range of non-
progressive syndromes of movement and posture
due to static injuries to the developing fetal or
infant central nervous system (CNS). Cerebral palsy
is estimated to occur in 2 to 3 of every 1,000 live
births, and in premature infants born before 28
weeks’ gestational age, the incidence rises up to 100
per 1,000.2
Advances in neonatal care have
improved the survival in newborns of low birth
weight and there has been a corresponding increase
in the incidence of cerebral palsy.3 Other factors
that are linked to the development of cerebral palsy
include multiple births, chorioamnionitis, antepar-
tum vaginal bleeding, second stage of labor lasting
longer than 4 hours, perinatal asphyxia, and perina-
tal infection.2,4,5,6,7,8 Following cerebral palsy, com-
mon causes of childhood spasticity are traumatic
brain injury, spinal cord injury, meningitis, ence-
phalitis, stroke, and pediatric multiple sclerosis.
Spasticity can result from any disease process
that impairs the upper motor neurons within the
CNS, causing a decrease in descending inhibitory
corticospinal and reticulospinal input to short-
latency stretch reflexes and a loss of functionally
important long-latency reflexes. Disinhibition of
short-latency reflex arcs leads to the hyperexcit-
ability of simple stretch reflexes. Combined with
reduced facilitation of functional, polysynaptic, or
long-latency reflexes, this results in a profound
alteration of proprioception.9 Initial maladaptive
hypertonic movement patterns, with reduced pro-
prioceptive feedback, lead to secondary viscoelas-
tic changes in muscle fiber, collagen tissue, and
tendon properties that propagate cycles of paresis,
contracture, and spasticity ( Fig. 47.1).10,11,12
Untreated, these changes can progress to joint and
muscular contractures, bony deformations, joint
subluxations and dislocations, and permanent loss
of joint mobility, contributing to weight loss, skin
breakdown, and chronic pain.10,11,13,14,15,16
47.3 Diagnosis and
Examination
The clinical evaluation of spasticity requires a
thorough accurate history with input from patient,
caretakers, and therapists. The history should
inquire about possible gestational and perinatal
events, the patient’s motor and cognitive mile-
stones, potential triggers of spasticity, family his-
tory of motor disorders, patient’s quality of life
and functional limitations.17,18 There are a variety
of complementary global and specific functional
measurement instruments; the gross motor per-
formance measure and pediatric evaluation of
disability index are generally considered the best
standard measures of function.19
The physical examination should include assess-
ments of motor power, muscle tone, active and
passive range of motion (PROM) and joints, deep
tendon reflexes, station, presence of limb deform-
ities or contractures, and spinal alignment.
Spasticity is di erentiated from other causes of
hypertonia by characteristic features including
velocity dependence, the clasp-knife phenomenon,
stroking a ect, and di erential distribution with
antigravity muscles.13,20 Spasticity can be quanti-
fied by rating systems such as the modified Ash-
worth scale, Tardieu scale, and pendulum test. The
modified Ashworth scale is the most widely used
in clinical practice and as an end point in clinical
trials, it does not require additional instruments
and is simple to administer (Box 47.1); however, it
does not di erentiate resistance due to spasticity
and fibrotic changes in muscle.21,22
Supplementary testing may involve imaging
studies such as cranial ultrasound, computed
tomography (CT), or magnetic resonance imaging
(MRI) in order to evaluate for hemorrhage, hydro-
cephalus, or other structural abnormalities of the
CNS. A majority of cerebral palsy patients have MR
368
abnormalities, with general patterns of gyral
anomalies, periventricular leukomalacia, and water-
shed cortical or deep gray nuclear damage.23,24
Preoperative MR findings may help predict post-
operative improvement, in particular, after selective
dorsal rhizotomy.25
47.4 Nonsurgical Management
The goal of management is to reduce spasticity
and halt the progression of contractures or
deformities in order to improve the ease of care-
giving, decrease pain, and increase quality of life.
47.4.1 Nonpharmacological
Therapy
Nonpharmacological therapy is used to maximize
range of motion, strengthen muscles, inhibit spas-
tic agonist muscles, and encourage adaptive motor
development. While controlled trials are limited,
physical and occupational therapy are mainstays
in the treatment of spasticity and are requisite for
surgical and medical interventions to achieve their
maximal benefit.26,27,28 Specific exercises that have
been shown to help reduce spasticity include
cycling, strengthening exercises, and treadmill
training.29,30,31,32,33 Static weight-bearing exercises
Fig. 47.1 Diagram depicting the cascade of mechanisms contributing to spastic movement disorders.
Surgical Management of Pediatric Spasticity
369
like standing with the assistance of tilt tables and
standing frames can reduce spasticity, improve
bone mineral density, prevent hip dislocation, and
improve bowel and urinary functions. In contrast,
passive stretching remains largely evidence-free
despite its widespread popularity.34,35,36
Con-
straint-induced therapy, in which temporary
splinting or casting is used to encourage utilization
and strengthening of less dominant muscle
groups, has received renewed attention in the past
decade due to positive results in adult stroke ther-
apy; constraint in cerebral palsy patients showed
better quality movements and structural neuro-
plastic changes.37,38 While the evidence of upper
extremity orthoses in children with cerebral palsy
is inconclusive, ankle–foot orthoses are commonly
used to treat dynamic equinus in cerebral palsy
and can reduce ankle excursion and increase dor-
siflexion in foot strike.39,40 The use of orthotics for
neurodevelopmental retraining are particularly
important during the periods of weakness follow-
ing botulinum toxin treatment.41
47.4.2 Oral Antispasticity Drugs
Oral antispasticity drugs can be used alongside an
e ective physical program or more invasive thera-
pies. Use of these drugs is patient-centered as the
drugs have di erent side e ect profiles. Baclofen,
diazepam, tizanidine, dantrolene, and gabapentin
are the most prescribed oral antispastic drugs
( Table 47.1).
Baclofen is the most widely used antispastic drug
in clinical practice, although most research involving
oral use has been conducted in adults. Baclofen
should be started at the lowest possible dose to
minimize side e ects such as sedation, somnolence,
and vertigo. It must be carefully tapered when start-
ing and discontinuing use in order to avoid central
side e ects of rebound spasticity, hallucinations,
hyperthermia, and seizures.42,43
Diazepam is e ective for short-term treatment
of spasticity, but there are no studies formally
addressing whether it improves motor function,
and caution of physical dependence with pro-
longed use has limited its long-term use.44 Clona-
zepam has been found to be particularly useful in
treating nocturnal spasms.13
Sodium dantrolene is the only major antispastic
drug that works at the muscle, rather than in the
nervous system. Although it has been shown to
Table 47.1 Oral medications utilized in the treatment of spasticity
Drug
Mechanism of action
Adverse effects
Baclofen
GABA agonist
Drowsiness, respiratory depression, ataxia, confusion
Diazepam
Benzodiazepine receptor agonist
Lethargy, rapid tolerance and dependence
Dantrolene
Blocks calcium efflux from muscle sarcoplasmic
reticulum
Weakness, hepatotoxicity, rash
Tizanidine
α2 adrenergic agonist
Sedation, dizziness, hypotension
Gabapentin
Alters voltage-gated calcium channel traffic
Dizziness, somnolence, nystagmus
Cannabinoids Cannabinoid receptor agonist
Palpitations, altered mentation, gastrointestinal
distress
Abbreviation: GABA, γ-aminobutyric acid.
Box 47.1 The modified Ashworth
scale, measuring the relative
spasticity in an individual muscle
group
The individual muscle group scores and mean
score for lower or upper extremities are fre-
quently used both in clinical practice and
research studies to approximate the objective
outcome of spasticity-reducing operations.
0 = No increase in muscle tone.
1 = Slight increase in muscle tone.
1 + = Slight increase in muscle resistance
throughout the range.
2 = Moderate increase in muscle tone through-
out the range of motion; passive movement is
easy.
3 = Marked increase in muscle tone throughout
the range of motion; passive movement is
di cult.
4 = Marked increase in muscle tone; a ected
part is rigid.
Functional Disorders
370
reduce spasticity in children with cerebral palsy, it
is infrequently used chronically due to hepatotox-
icity.43,45
Tizanidine has been found to be able to reduce
spasticity in studies with adults with multiple
sclerosis and spinal cord injury and in small stud-
ies with children with cerebral palsy. While
muscle weakness may be seen less with tizanidine
than baclofen, tizanidine may have cardiovascular,
CNS, and hepatotoxic e ects that must be taken
into account.46
Gabapentin has been shown in small studies to
have good tolerability and benefits for spasticity,
but has mostly been investigated in the context of
spinal cord injury or multiple sclerosis.47 Cannabi-
noids have been of interest recently as a treatment
for pain and spasticity in adults with multiple scle-
rosis, but have not been used in children.47
47.4.3 Intramuscular Injections
Intramuscular injections of alcohol, phenol, and
botulinum toxin produce neuromuscular block-
ades that can help treat focal spasticity or manage
problem muscle groups in more generalized spas-
ticity.
Five to seven percent phenol or 45% alcohol
injections perineurally or into the motor point of
selected muscles induce necrosis of axons in
hyperexcitable anterior horn cells. This produces a
reduction in limb tone that can last up to 12
months when phenol is used and 2 to 5 months
when alcohol is used. The sustained reduction in
tone and relative low cost of phenol injections are
balanced with side e ects including pain and dys-
esthesia due to necrosis of secondary axons in the
peripheral nerve, lethargy, and nausea due to sys-
temic absorption, and potential necrosis at the
injection site. Both treatments are rarely used
today due to the advent of botulinum toxin
therapy.43
Botulinum toxin acts to inhibit the release of
acetylcholine at the neuromuscular junction, and
today, it is the most commonly used pharmacolog-
ical injection for the management of spasticity.
The e ects of botulinum toxin generally begin 1 to
3 days, peaking at 21 days, and dissipating by 3 to 4
months. It is licensed for the treatment of dynamic
equinus foot in pediatric cerebral palsy, and there is
good evidence for its use at calf, hip, adductor, ham-
string, and upper limb levels.48,49,50,51,52 Botulinum
toxin is well tolerated, but has rare side e ects
that include respiratory infection, seizures,
m uscle atrophy, im m unoresistance, and transient
pain at injection site.53,54,55 General dosing guide-
lines are 2 to 6 U/kg and should take into account
the child’s m uscle bulk and degree of spasticity.
The use of electromyography, m uscle stim ulators,
or direct ultrasound guidance for the correct
adm inistration to targeted areas is increasingly
com m on.56 Postinjection care should include a
comprehensive physiotherapy and follow-up for
repeated or m ultilevel injections to accelerate
functional outcom es and m inim ize the need for
orthopedic intervention.41,50,57
47.4.4 Complementary Medicine
Complementary medicine, including hyperbaric
oxygen, craniospinal osteopathy, and acupuncture
has been used internationally for the management
of spasticity in children; these treatments have
been found to be useful in individual cases, but for
most, there is little supportive evidence.58,59
47.5 Surgical Indications
A wide array of surgical options is available for the
treatment of spasticity, allowing for various options
based on the patient’s clinical characteristics and
the goals of treatment. Spasticity reducing opera-
tions will not resolve already established orthopedic
issues such as contractures, joint subluxation, dislo-
cation, or bony deformity. Early reduction in tone
has been shown to reduce the development of
orthopedic issues and, thus, operations to reduce
tone should be considered prior to the onset of
orthopedic problems when possible.60,61
Younger patients with the greatest amount of
spasticity in the lower extremities are most likely
to obtain the greatest functional benefit from
selective dorsal rhizotomy (SDR), but functional
benefit can be obtained at older ages as well.61,62
Studies have also demonstrated that patients can
have a reduction in spasticity and functional
improvement in the upper extremities after SDR,
but to a lesser extent than in the lower extrem-
ities.63,64,65,66
Intrathecal baclofen (ITB) pumps are most
clearly indicated in patients with severe spastic
quadriplegia that are dependent on caregivers.
This therapy is also e ective in older adolescents.67
At some centers, patients being considered for
baclofen therapy undergo a trial injection of 50 to
100 µg intrathecally. Antispastic e ects are typi-
cally seen within 2 to 4 hours after lumbar punc-
ture and wear o by 8 hours. A reduction in tone
Surgical Management of Pediatric Spasticity
371
by one point or more on the Ashworth scale is con-
sidered a positive response, and is seen in the vast
majority of patients undergoing trials.17,68 Impor-
tantly, patients and caregivers can temporarily
assess the realistic level of tone reduction and bene-
fit from ITB on spasticity and joint mobility.
Patients in whom function-impairing spasticity is
located to a single or a few muscle groups in an
extremity may choose botulinum toxin injections as
the best option.52,69 There are few side e ects due to
its localized delivery, with the primary risk being an
allergic reaction.70,71 Botulinum toxin injections and
baclofen pumps have largely supplanted the older
technique of selective neurotomy. However, in
contrast to botulinum toxin injections, selective
neurotomy o ers a longer-lasting reduction in
tone and can also be performed to provide partial
denervation of the muscle group based on intraope-
rative neurophysiologic monitoring and stimulation,
allowing for a balance between spasticity and motor
weakness.72,73
47.5.1 Surgical Technique
Selective Dorsal Rhizotomy
The patient is positioned prone and draped to allow
adequate exposure of the lower back. Although this
procedure is often performed with a five-level lami-
nectomy or laminoplasty to expose the roots as they
exit the spinal canal, we prefer the SDR through a
single laminectomy as popularized by Park et al
( Fig. 47.2).74 A single-level laminectomy at the L1
level is performed and access to the conus cauda
Fig. 47.2 Illustration of key steps during selective dorsal rhizotomy. (a) The innervation pattern of each dorsal root is
examined using electrophysiogical stimulation using a threshold voltage. (b) The dorsal root is subdivided into three to
seven smaller rootlets. (c) Each rootlet is tested to determine the relative level of spasticity generated with stimulation.
(d) Rootlets to be preserved are placed behind the Silastic sheet. (e) Rootlets with the greatest spastic responses are
sectioned. (f) The remaining dorsal roots to be examined are kept above the Silastic sheet. Section rootlets are displaced
laterally. Spared rootlets are meticulously kept below the sheet. (Reproduced with permission from Oxford University
Press.)
Functional Disorders
372
equina junction is confirmed via ultrasound prior to
opening the dura.74 Nerve roots are isolated and
tested using electrical stimulation and neurophysio-
logical monitoring. Ventral roots are separated from
dorsal roots and each dorsal root is separated into
four to eight rootlets. Individual dorsal rootlets are
then stimulated to determine which should be
transected based on the relative severity of the spas-
ticity elicited. Stimulated sensory rootlets that dem-
onstrate sphincter innervation or normal responses
are preserved, while rootlets demonstrating spastic
responses when stimulated are transected. Intra-
operative palpation of muscle groups during rootlet
stimulation by a physical and occupational therapy
team or physiatrist is helpful in providing physiolog-
ical feedback when determining which rootlets
to transect based on the degree of spasticity elicited.
With the single-level laminectomy surgical
approach, ventral roots are easily identified via elec-
trophysiological stimulation.75 Many centers per-
form transection of 40% or less of rootlets due to
concerns such as iatrogenic neurological deficits.76,
77,78,79,80 However, other centers including ours sup-
port aggressively transecting up to 70% of rootlets
based on data suggesting that relief of spasticity is
proportional to the percent of dorsal nerve tissue
transected.63,78,81
Intrathecal Baclofen Pump
The appropriate surgical techniques for ITB have
been previously described.82 Briefly, the patient is
positioned in the lateral decubitus position to
allow for both implantation of the pump in the
anterior abdominal wall and insertion of the cath-
eter tip into the subarachnoid space. The side of
pump placement should be dictated by patient
preference and existence of coexisting hardware
such as a percutaneous gastrostomy tube. Both
subcutaneous or subfascial placement are possible,
with the latter favored in patients with low tissue
volume that will be more prone to hardware ero-
sion.83 The abdominal incision is made and a sub-
cutaneous plane is dissected and expanded for
subcutaneous placement, if desired. For subfascial
placement, the external oblique fascia and rectus
abdominis fascia are identified and an incision is
made followed by blunt dissection to develop a
space between the fascial and muscle layers.
The location of catheter placement is dependent
on the distribution of spasticity, with higher place-
ment being indicated in the setting of increased
upper extremity tone. For spastic diplegia, the
catheter is threaded from insertion at L3–L4 or L4–
L5 to rest in the region of T10–T12. For spastic
quadriparesis, the catheter can be threaded further
upward to C5–T2.82 Confirmation of placement is
performed using fluoroscopic guidance. Flexible
tubing is tunneled subcutaneously around the
flank to the lumbar spine to connect the catheter
and pump. Intermittent refilling is generally
required every 2 to 6 months based on dosing
parameters.
Selective Neurotomy
The patient is draped and positioned based on the
muscle groups in question. Ideally, the limb being
operated is sterilized and draped in such a way to
allow intraoperative assessment of tone by the
surgeon. Localization of the nerve is performed
using anatomical landmarks and refined based on
neurophysiological testing with a sharp probe
( Table 47.2). Temporary anesthetic blocks may
be performed to determine the contribution of
spasticity versus orthopedic complications for a
given joint in order to determine the likely func-
tional benefit of neurotomy.84 Subsequent to inci-
sion and subcutaneous dissection, an operative
microscope is used to identify individual motor
nerve fibers. Nerve stimulation is then used to
determine the most spastic fibers, which are then
obliterated.
47.5.2 Complications
Selective Dorsal Rhizotomy
Selective dorsal rhizotomy is a well-tolerated
procedure with a very low risk of permanent mor-
bidity. Urinary retention from nerve root manipu-
lation may be seen transiently, but permanent
urinary dysfunction is rare.85,86,87,88 Urinary cathe-
terization from nerve room manipulation and
anesthesia may be seen transiently. Transient dys-
esthesia and hypoesthesia are also frequently
reported within the first few postoperative weeks,
but permanent neurological complaints after SDR
occur in less than 5% of patients. An even smaller
percentage of patients have any type of functional
decline after SDR.88,89,90,91,92 Older studies have
drawn attention to the possibility of an increased
incidence of scoliosis after SDR.93,94 As this is a
common finding in children with spasticity without
SDR, it is unclear what role SDR plays in the devel-
opment of scoliosis and whether this relationship
exists in the era of single-level laminectomy rather
Surgical Management of Pediatric Spasticity
373
Table 47.2 Indication, location of incision, and key anatomical landmarks for common nerves targeted with selective
neurotomy
Nerve
Indication
Incision location
Nerve anatomical
landmarks
Lateral pectoral
nerve
Spasticity of shoulder with
internal rotation and
adduction
Curvilinear incision over infra-
clavicular fossa in medial part
of deltopectoral groove
Deep to partially reflected
clavipectoral fascia and pec-
toralis major
Teres major nerve
Spasticity of shoulder with
internal rotation and
adduction
Incision along inner border of
teres major from lower border
of posterior head of deltoid to
lower extremity of scapula
In space separating teres ma-
jor from teres minor and other
infraspinatus muscles
Midway between long portion
of triceps brachii above and
insertions of teres major on
infraspinatus aponeurosis
below
Musculocutaneous
nerve
Spasticity of elbow with
flexion
Longitudinal incision from in-
ferior edge of pectoralis ma-
jor, medial to biceps brachii
muscle
Anterior and medial to bra-
chialis muscle
Median nerve
Spasticity of forearm with
pronation deformity, flexion
deformity in wrist, swan-neck
deformity of fingers
Curvilinear incision above
flexion line of elbow, medial
to biceps brachii tendon,
through elbow and before
junction of upper and middle
third of anterior forearm
Medial to brachial artery, deep
to lacertus fibrosus
Recurrent branch of
median nerve
Thumb-in-palm deformity
Curvilinear carpal incision
Deep to transverse carpal
ligament
Ulnar nerve
Spastic wrist flexion, adduc-
tion/flexion deformity of
thumb
Longitudinal or arched inci-
sion between two heads of
flexor carpi ulnaris
Medial to medial epicondyle
between heads of flexor carpi
ulnaris proximally
Obturator nerve
Spasticity of adductor
muscles, diplegic children
with scissoring, facilitation of
perineal toileting and self-
catheterization
Longitudinal incision ex-
tended distally from point just
below groin over belly of
adductor longus
Transverse incision in hip
flexion fold centered on
prominence of adductor lon-
gus tendon (aesthetically
preferred)
Anterior branch is lateral to
adductor longus
Posterior branch is deep and
should be spared to preserve
stabilizing muscles
Sciatic nerve
Spastic diplegia with flexion
deformity of knees
Longitudinal straight incision
on posterior thigh between
ischial tuberosity and tip of
femoral greater trochanter
Deep to gluteus maximus and
biceps femoris
Femoral nerve
Spasticity of quadriceps,
limited knee flexion during
swing phase of gait
Horizontal incision in hip flex-
ion fold, medial to sartorius
muscle
Nerve to rectus femoris
muscle is superficial to nerve
to vastus intermedius
Tibial nerve
Spastic varus plantar flexion
with or without claw toes
Z-shaped incision over popli-
teal fossa
Deep to popliteal fascia,
superficial to popliteal artery
and vein
Sensory medial cutaneous
nerve is encountered first and
should be spared
Superior soleus nerve is mid-
line and posterior to tibial
nerve
Functional Disorders
374
than multilevel laminectomies. In addition, SDR
does not eliminate the need for future orthopedic
surgery. Approximately 34% of patients who are
operated on between the ages of 2 and 5 years may
ultimately still require surgery for orthopedic com-
plications within 7.5 years after SDR.95,96 However,
this is in contrast to the approximately 60% of
patients with spasticity at birth who without SDR
will require an orthopedic procedure by the age of
8.95,97
Intrathecal Baclofen Pump
The body habitus and disability of patients under-
going pump placement contributes to a postopera-
tive wound infection rate of 5 to 36%. More than
half of these wound infections are severe enough
to require removal of the pump hardware.98,99,100
Cerebrospinal fluid (CSF) leakage occurs fre-
quently, but can typically be resolved without
operative repair or removal of the hardware.98
Pump failure requiring replacement occurs in 5
to 10% of cases and failure of the catheter itself
may occur as much as in 35% of early cases,
though increased use and quality of the devices
has lowered this to less than 10% in more recent
studies.98,99,101,102,103,104
ITB infusions also harbor some risk. Most com-
monly, baclofen is often associated with mild seda-
tion, which is easily resolved by lowering the does.
More serious symptoms such dizziness, blurred
vision, nausea, confusion, and slurred speech have
also been reported on occasion.102 Baclofen with-
drawal is a serious condition resulting in rebound
spasticity, tachycardia, hyperthermia, itching,
paresthesias, and seizures. It is best managed
through extensive education to the patient and
family.105,106 New-onset seizure or increased seiz-
ure frequency has been reported but typically
resolve with repair of any device malfunction and
short-term seizure prophylaxis.101,107 Severe respi-
ratory, neurological, or cardiovascular depression
can occur during overdose scenarios and often are
accompanied by weakness, flaccidity, and areflexia
in all extremities. Reduction of the baclofen dose
while supporting the patient’s cardiovascular and
respiratory status allows for continuation of the
therapy after the crisis.101
Selective Neurotomy
Postoperative complications vary based on the
specific location and nerve, but are typically
transient in nature. Hematoma formation, infec-
tion, hypoesthesia, and weakness of the a ected
limb have been reported with rates ranging from 0
to 5%.84,108,109
47.5.3 Postoperative Care
Postsurgical pain from surgical exploration and
pump implantation as well as laminectomy and
nerve root manipulation is common. For postope-
rative pain following SDR, intravenous, epidural,
and transthecal approaches to pain management
have been reported, with morphine or fentanyl
typically being the medication of choice in a sur-
vey of 59 centers worldwide. In more than half of
cases, continuous infusion can be discontinued in
1 to 4 days, but may be required for up to 1 week
followed by several additional days of oral opioids.
The duration of pain management has not been
found to be associated with drug of choice or
mechanism of delivery.110 In our center, we have
had excellent results with the combination of
intravenous toradol and diazepam, with additional
morphine for breakthrough pain.17,111
As well as pain management, the primary goal
of postoperative care is to maximize the long-term
benefit from reduced spasticity and improved
function.26,76,112 Existing data suggest that patients
may benefit from physiotherapy beyond the post-
operative period.26 Appropriate therapy is best
obtained in conjunction with trained therapists
who can accurately assess the physical presenta-
tion and key barriers to function, set appropriate
goals, choose the appropriate intervention, and
reassess following implementation.113 These inter-
ventions typically focus on muscle lengthening,
muscle strength, and motor memory, and plan-
ning. Temporary splinting and casting may assist
patients in muscle lengthening between sessions
when deemed necessary, as severely spastic
children may require hours of stretching daily to
prevent progression to contracture.114 As well as
traditional muscle strengthening exercises, high
activity levels in daily life tapered to physical and
mental disabilities should also be encouraged.115
47.5.4 Outcomes
Selective Dorsal Rhizotomy
There have been a number of excellent long-term
outcome studies for selective dorsal rhizotomy.
The outcome measures examined include muscle
Surgical Management of Pediatric Spasticity
375
tone, flexibility, gait pattern, functional position-
ing, and the ability of the child to deal with his or
her environment. Nearly all studies investigating
SDR have demonstrated a significant and persis-
tent decrease in spasticity without a return of
hypertonicity over time. Improved function and
ambulation are commonly seen regardless of the
preoperative abilities.116,117,118 After SDR, 50 to
78% of patients with impaired ambulation have
been found to improve to a higher level of inde-
pendence (e.g., walk with assistance to walk with
walker alone).119 More recently, long-term out-
come data for children with spastic diplegia who
underwent SDR in Capet own have been pub-
lished.117 In this prospective cohort study, the data
demonstrated that significant improvements in
both range of motion and quality of gait (cadence
and step length) persisted over a 20-year period.
Importantly, SDR did not abolish the need for sub-
sequent orthopedic surgery, as approximately half
of these children still required lengthening of the
rectus femoris, hamstrings, and/or Achilles’ tendon.
McLaughlin et al reported a comparative analy-
sis and meta-analysis of three randomized clinical
trials in 2002.77,78 Eighty-two children with spastic
diplegia received either SDR and physiotherapy or
physiotherapy alone. Outcome measures were
used for spasticity (Ashworth’s scale) and function
(gross motor function measure) and applied at a
12-month follow-up visit. Overall, selective dorsal
rhizotomy with physical therapy was more e ec-
tive than physical therapy alone in reducing spas-
ticity and improving overall function in children
with spastic diplegia.
Although many studies have documented the
e cacy of SDR and ITB therapy on the treatment
of spasticity, only recently has information com-
paring these treatments directly become avail-
able.118 Kan and colleagues reported a consecutive
series of 71 children who underwent SDR for spas-
ticity and compared them with another group of
71 children who underwent ITB therapy matched
by age and preoperative score on the gross motor
function classification system (GMFCS).118 At 1
year postoperatively, both SDR and ITB therapy
decreased tone, increased PROM, and improved
function. Compared with ITB therapy, however,
SDR provided a significantly larger magnitude of
improvement in tone, PROM, and gross motor
function. In addition, fewer patients in the SDR
group required subsequent orthopedic procedures
(19.1 vs. 40.8%).
SDR has typically been only used for children
with spastic diplegia due to the unpredictable
e ects of SDR on the upper extremities. However,
numerous examples of suprasegmental improve-
ments in the upper extremities have now been
reported in patients with spastic quadriplegia
undergoing SDR.63,120 Most recently, Gigante et al
demonstrated that over 90% of patients with upper
extremity spasticity had a reduction in tone and
over 70% had an increase in motor control or spon-
taneous movement of the upper extremities after
SDR.63
Intrathecal Baclofen Pump
Multiple clinical trials have demonstrated that ITB
therapy is e ective at decreasing spasticity and
improving functional outcome.68,99,121,122
The
degree of ambulation was found to be improved in
28 to 43% of patients.123,124,125 In the original mul-
ticenter randomized controlled trial, 100% of
patients randomized into the baclofen group were
found to have at least a 1 point reduction on the
mean Ashworth scale for their lower extrem-
ities.122 This was subsequently supported in a pre-
dominantly pediatric trial of quadriplegic patients,
all of which met the same criteria for reduced
spasticity in upper and lower extremities on long-
term follow-up. Further, it was found that, in all
age groups, the required amount of baclofen
needed to maintain this reduced spasticity tended
to titrate upward toward twice the original dose
during the initial 2 postoperative years, followed
by a leveling o and stabilization of the dose.121
Perhaps the greatest benefit for ITB therapy is
that it is a nondestructive procedure for which
dosing can be adjusted to fit each patient’s needs.
However, vigilant maintenance is required with
ITB therapy; as discussed above, patients may have
a higher risk of complications and need for reope-
rations, particularly in patients under the age of 10
or with a mean Ashworth score of 3 or greater.98
Selective Neurotomy
Selective neurotomy is e ective at increasing the
postoperative passive and active range-of-motion
of joints, and allows for a greater utilization of
function of the limb, and reduces spasticity of the
associated muscle groups.72,84
However, most
available data are in the form of small cohorts lack-
ing in long-term follow-up. In contrast to SDR,
there may be a higher rate of recurrence of spastic-
ity following neurotomy. Approximately 15% of
adult cases witness a partial or complete return of
spasticity at 6 months and 37% at 17 months.84,126
Functional Disorders
376
Patients undergoing repeat neurotomy seem to
benefit a similar degree as first time cases.84 Data
are lacking to support the widespread utility of
this operation in children, in whom long-term
reduction of spasticity is crucial given the number
of years of expected life, and thus this technique is
generally reserved for a highly select group of
patients with focal spasticity.
References
[1] Sanger TD, Delgado MR, Gaebler-Spira D, Hallett M, Mink
JW, Task Force on Childhood Motor Disorders. Classification
and definition of disorders causing hypertonia in childhood.
Pediatrics. 2003; 111(1):e89–e97
[2] O’Shea TM. Cerebral palsy in very preterm infants: new
epidemiological insights. Ment Retard Dev Disabil Res Rev.
2002; 8(3):135–145
[3] Koman LA, Smith BP, Shilt JS. Cerebral palsy. Lancet. 2004;
363(9421):1619–1631
[4] Jarvis S, Glinianaia SV, Torrioli MG, et al. Surveillance of
Cerebral Palsy in Europe (SCPE) Collaboration of European
Cerebral Palsy Registers. Cerebral palsy and intrauterine
growth in single births: European collaborative study.
Lancet. 2003; 362(9390):1106–1111
[5] Nelson KB. The epidemiology of cerebral palsy in term
infants. Ment Retard Dev Disabil Res Rev. 2002; 8(3):
146–150
[6] Yeargin-Allsopp M, Van Naarden Braun K, Doernberg NS,
Benedict RE, Kirby RS, Durkin MS. Prevalence of cerebral
palsy in 8-year-old children in three areas of the United
States in 2002: a multisite collaboration. Pediatrics. 2008;
121(3):547–554
[7] O’Shea TM, Dammann O. Antecedents of cerebral palsy in
very low-birth weight infants. Clin Perinatol. 2000; 27(2):
285–302
[8] O’Shea TM, Preisser JS, Klinepeter KL, Dillard RG. Trends in
mortality and cerebral palsy in a geographically based
cohort of very low birth weight neonates born between
1982 to 1994. Pediatrics. 1998; 101(4 pt 1):642–647
[9] Dietz V. Proprioception and locomotor disorders. Nat Rev
Neurosci. 2002; 3(10):781–790
[10] Dietz V, Sinkjaer T. Spasticity. Handb Clin Neurol. 2012;
109:197–211
[11] Gracies JM. Pathophysiology of spastic paresis. II:
Emergence of muscle overactivity. Muscle Nerve. 2005; 31
(5):552–571
[12] Gracies JM. Pathophysiology of spastic paresis. I: Paresis and
soft tissue changes. Muscle Nerve. 2005; 31(5):535–551
[13] Kheder A, Nair KP. Spasticity: pathophysiology, evaluation
and management. Pract Neurol. 2012; 12(5):289–298
[14] Burke D, Wissel J, Donnan GA. Pathophysiology of spasticity
in stroke. Neurology. 2013; 80(3) suppl 2:S20–S26
[15] Ward T. Spasticity in children with non-progressive brain
disorders. Nurs Times. 2012; 108(47):23
[16] Ward AB. A literature review of the pathophysiology and
onset of post-stroke spasticity. Eur J Neurol. 2012; 19(1):
21–27
[17] Mandigo CE, Anderson RC. Management of childhood
spasticity: a neurosurgical perspective. Pediatr Ann. 2006;
35(5):354–362
[18] Allen MC, Alexander GR. Using motor milestones as a
multistep process to screen preterm infants for cerebral
palsy. Dev Med Child Neurol. 1997; 39(1):12–16
[19] Ketelaar M, Vermeer A, Helders PJ. Functional motor
abilities of children with cerebral palsy: a systematic
literature review of assessment measures. Clin Rehabil.
1998; 12(5):369–380
[20] Capute AJ. Identifying cerebral palsy in infancy through
study of primitive-reflex profiles. Pediatr Ann. 1979; 8(10):
589–595
[21] Bohannon RW, Smith MB. Interrater reliability of a modified
Ashworth scale of muscle spasticity. Phys Ther. 1987; 67(2):
206–207
[22] Mutlu A, Livanelioglu A, Gunel MK. Reliability of Ashworth
and modified Ashworth scales in children with spastic
cerebral palsy. BMC Musculoskelet Disord. 2008; 9:44
[23] Truwit CL, Barkovich AJ, Koch TK, Ferriero DM. Cerebral
palsy: MR findings in 40 patients. AJNR Am J Neuroradiol.
1992; 13(1):67–78
[24] Ashwal S, Russman BS, Blasco PA, et al. Quality Standards
Subcommittee of the American Academy of Neurology,
Practice Committee of the Child Neurology Society. Practice
parameter: diagnostic assessment of the child with cerebral
palsy: report of the Quality Standards Subcommittee of the
American Academy of Neurology and the Practice
Committee of the Child Neurology Society. Neurology.
2004; 62(6):851–863
[25] Grunt S, Becher JG, van Schie P, van Ouwerkerk WJ, Ahmadi
M, Vermeulen RJ. Preoperative MRI findings and functional
outcome after selective dorsal rhizotomy in children with
bilateral spasticity. Childs Nerv Syst. 2010; 26(2):191–198
[26] Palmer FB, Shapiro BK, Wachtel RC, et al. The e ects of
physical therapy on cerebral palsy. A controlled trial in
infants with spastic diplegia. N Engl J Med. 1988; 318(13):
803–808
[27] Cada EA, O’Shea RK. Identifying barriers to occupational and
physical therapy services for children with cerebral palsy. J
Pediatr Rehabil Med. 2008; 1(2):127–135
[28] Watanabe T. The role of therapy in spasticity management.
Am J Phys Med Rehabil. 2004; 83 suppl 10:S45–S49
[29] Verschuren O, Ketelaar M, Gorter JW, Helders PJ, Uiterwaal
CS, Takken T. Exercise training program in children and
adolescents with cerebral palsy: a randomized controlled
trial. Arch Pediatr Adolesc Med. 2007; 161(11):1075–1081
[30] Ada L, Dorsch S, Canning CG. Strengthening interventions
increase strength and improve activity after stroke: a
systematic review. Aust J Physiother. 2006; 52(4):241–248
[31] McBurney H, Taylor NF, Dodd KJ, Graham HK. A qualitative
analysis of the benefits of strength training for young
people with cerebral palsy. Dev Med Child Neurol. 2003; 45
(10):658–663
[32] Damiano DL, Arnold AS, Steele KM, Delp SL. Can strength
training predictably improve gait kinematics? A pilot study
on the e ects of hip and knee extensor strengthening on
lower-extremity alignment in cerebral palsy. Phys Ther.
2010; 90(2):269–279
[33] Dodd KJ, Taylor NF, Damiano DL. A systematic review of the
e ectiveness of strength-training programs for people with
cerebral palsy. Arch Phys Med Rehabil. 2002; 83(8):1157–
1164
[34] Ketelaar M, Vermeer A, Hart H, van Petegem-van Beek E,
Helders PJ. E ects of a functional therapy program on motor
abilities of children with cerebral palsy. Phys Ther. 2001; 81
(9):1534–1545
Surgical Management of Pediatric Spasticity
377
[35] Pin T, Dyke P, Chan M. The e ectiveness of passive
stretching in children with cerebral palsy. Dev Med Child
Neurol. 2006; 48(10):855–862
[36] Pin TW. E ectiveness of static weight-bearing exercises in
children with cerebral palsy. Pediatr Phys Ther. 2007; 19(1):
62–73
[37] Sterling C, Taub E, Davis D, et al. Structural neuroplastic
change after constraint-induced movement therapy in
children with cerebral palsy. Pediatrics. 2013; 131(5):
e1664–e1669
[38] Taub E, Ramey SL, DeLuca S, Echols K. E cacy of constraint-
induced movement therapy for children with cerebral palsy
with asymmetric motor impairment. Pediatrics. 2004; 113
(2):305–312
[39] Carlson WE, Vaughan CL, Damiano DL, Abel MF. Orthotic
management of gait in spastic diplegia. Am J Phys Med
Rehabil. 1997; 76(3):219–225
[40] Autti-Rämö I, Suoranta J, Anttila H, Malmivaara A, Mäkelä
M. E ectiveness of upper and lower limb casting and
orthoses in children with cerebral palsy: an overview of
review articles. Am J Phys Med Rehabil. 2006; 85(1):89–103
[41] Leach J. Children undergoing treatment with botulinum
toxin: the role of the physical therapist. Muscle Nerve
Suppl. 1997; 6:S194–S207
[42] Delgado MR, Hirtz D, Aisen M, et al. Quality Standards
Subcommittee of the American Academy of Neurology and
the Practice Committee of the Child Neurology Society.
Practice parameter: pharmacologic treatment of spasticity
in children and adolescents with cerebral palsy (an
evidence-based review): report of the Quality Standards
Subcommittee of the American Academy of Neurology and
the Practice Committee of the Child Neurology Society.
Neurology. 2010; 74(4):336–343
[43] Papavasiliou AS. Management of motor problems in
cerebral palsy: a critical update for the clinician. Eur J
Paediatr Neurol. 2009; 13(5):387–396
[44] Verrotti A, Greco R, Spalice A, Chiarelli F, Iannetti P.
Pharmacotherapy of spasticity in children with cerebral
palsy. Pediatr Neurol. 2006; 34(1):1–6
[45] Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler
F. Dantrolene—a review of its pharmacology, therapeutic
use and new developments. Anaesthesia. 2004; 59(4):
364–373
[46] Wagsta AJ, Bryson HM. Tizanidine. A review of its
pharmacology, clinical e cacy and tolerability in the
management of spasticity associated with cerebral and
spinal disorders. Drugs. 1997; 53(3):435–452
[47] Stevenson VL. Rehabilitation in practice: spasticity
management. Clin Rehabil. 2010; 24(4):293–304
[48] Russman BS, Tilton A, Gormley ME, Jr. Cerebral palsy: a
rational approach to a treatment protocol, and the role of
botulinum toxin in treatment. Muscle Nerve Suppl. 1997; 6:
S181–S193
[49] Steenbeek D, Meester-Delver A, Becher JG, Lankhorst GJ. The
e ect of botulinum toxin type A treatment of the lower
extremity on the level of functional abilities in children with
cerebral palsy: evaluation with goal attainment scaling. Clin
Rehabil. 2005; 19(3):274–282
[50] Ward AB. Spasticity treatm ent with botulinum toxins. J
Neural Transm (Vienna). 2008; 115(4):607–616
[51] Sutherland DH, Kaufman KR, Wyatt MP, Chambers HG,
Mubarak SJ. Double-blind study of botulinum A toxin
injections into the gastrocnemius muscle in patients with
cerebral palsy. Gait Posture. 1999; 10(1):1–9
[52] Koman LA, Mooney JF, III, Smith BP, Walker F, Leon JM,
BOTOX Study Group. Botulinum toxin type A
neuromuscular blockade in the treatment of lower
extremity spasticity in cerebral palsy: a randomized,
double-blind, placebo-controlled trial. J Pediatr Orthop.
2000; 20(1):108–115
[53] Turkel CC, Bowen B, Liu J, Brin MF. Pooled analysis of the
safety of botulinum toxin type A in the treatment of
poststroke spasticity. Arch Phys Med Rehabil. 2006; 87(6):
786–792
[54] Hastings-Ison T, Graham HK. Atrophy and hypertrophy
following injections of botulinum toxin in children with
cerebral palsy. Dev Med Child Neurol. 2013; 55(9):778–779
[55] Goldstein EM. Safety of high-dose botulinum toxin type A
therapy for the treatment of pediatric spasticity. J Child
Neurol. 2006; 21(3):189–192
[56] Schroeder AS, Berweck S, Lee SH, Heinen F. Botulinum toxin
treatment of children with cerebral palsy—a short review of
di erent injection techniques. Neurotox Res. 2006; 9(2–3):
189–196
[57] Wallen M, O’Flaherty SJ, Waugh MC. Functional outcomes of
intramuscular botulinum toxin type a and occupational
therapy in the upper limbs of children with cerebral palsy: a
randomized controlled trial. Arch Phys Med Rehabil. 2007;
88(1):1–10
[58] Hurvitz EA, Leonard C, Ayyangar R, Nelson VS.
Complementary and alternative medicine use in families of
children with cerebral palsy. Dev Med Child Neurol. 2003;
45(6):364–370
[59] Glew GM, Fan MY, Hagland S, Bjornson K, Beider S,
McLaughlin JF. Survey of the use of massage for children
with cerebral palsy. Int J Ther Massage Bodywork. 2010; 3
(4):10–15
[60] Tilton AH. Therapeutic interventions for tone abnormalities
in cerebral palsy. NeuroRx. 2006; 3(2):217–224
[61] Tilton A. Management of spasticity in children with cerebral
palsy. Semin Pediatr Neurol. 2009; 16(2):82–89
[62] Steinbok P. Selection of treatment modalities in children
with spastic cerebral palsy. Neurosurg Focus. 2006; 21(2):e4
[63] Gigante P, McDowell MM, Bruce SS, et al. Reduction in
upper-extremity tone after lumbar selective dorsal
rhizotomy in children with spastic cerebral palsy. J
Neurosurg Pediatr. 2013; 12(6):588–594
[64] Ghotbi N, Ansari NN, Naghdi S, Hasson S, Jamshidpour B,
Amiri S. Inter-rater reliability of the modified Ashworth
Scale in assessing lower limb muscle spasticity. Brain Inj.
2009; 23(10):815–819
[65] Loewen P, Steinbok P, Holsti L, MacKay M. Upper extremity
performance and self-care skill changes in children with
spastic cerebral palsy following selective posterior
rhizotomy. Pediatr Neurosurg. 1998; 29(4):191–198
[66] Ojemann JG, McKinstry RC, Mukherjee P, Park TS, Burton H.
Hand somatosensory cortex activity following selective
dorsal rhizotomy: report of three cases with fMRI. Childs
Nerv Syst. 2005; 21(2):115–121
[67] Armstrong RW, Steinbok P, Cochrane DD, Kube SD, Fife SE,
Farrell K. Intrathecally administered baclofen for treatment
of children with spasticity of cerebral origin. J Neurosurg.
1997; 87(3):409–414
[68] Awaad Y, Tayem H, Munoz S, Ham S, Michon AM, Awaad R.
Functional assessment following intrathecal baclofen
therapy in children with spastic cerebral palsy. J Child
Neurol. 2003; 18(1):26–34
[69] Corry IS, Cosgrove AP, Walsh EG, McClean D, Graham HK.
Botulinum toxin A in the hemiplegic upper limb: a double-
blind trial. Dev Med Child Neurol. 1997; 39(3):185–193
[70] Baker R, Jasinski M, Maciag-Tymecka I, et al. Botulinum toxin
treatment of spasticity in diplegic cerebral palsy: a
Functional Disorders
378
randomized, double-blind, placebo-controlled, dose-
ranging study. Dev Med Child Neurol. 2002; 44(10):666–
675
[71] Francisco GE. Botulinum toxin: dosing and dilution. Am J
Phys Med Rehabil. 2004; 83 suppl 10:S30–S37
[72] Fitoussi F, Ilharreborde B, Presedo A, Souchet P, Penneçot GF,
Mazda K. Shoulder external rotator selective neurotomy in
cerebral palsy: anatomical study and preliminary clinical
results. J Pediatr Orthop B. 2010; 19(1):71–76
[73] Sitthinamsuwan B, Chanvanitkulchai K, Nunta-Aree S,
Kumthornthip W, Pisarnpong A, Ploypetch T. Combined
ablative neurosurgical procedures in a patient with mixed
spastic and dystonic cerebral palsy. Stereotact Funct
Neurosurg. 2010; 88(3):187–192
[74] Park TS, Ga ney PE, Kaufman BA, Molleston MC. Selective
lumbosacral dorsal rhizotomy immediately caudal to the
conus medullaris for cerebral palsy spasticity. Neurosurgery.
1993; 33(5):929–933, discussion 933–934
[75] Steinbok P, Tidemann AJ, Miller S, Mortenson P, Bowen-
Roberts T. Electrophysiologically guided versus non-
electrophysiologically guided selective dorsal rhizotomy for
spastic cerebral palsy: a comparison of outcomes. Childs
Nerv Syst. 2009; 25(9):1091–1096
[76] Steinbok P, Reiner AM, Beauchamp R, Armstrong RW,
Cochrane DD, Kestle J. A randomized clinical trial to
compare selective posterior rhizotomy plus physiotherapy
with physiotherapy alone in children with spastic diplegic
cerebral palsy. Dev Med Child Neurol. 1997; 39(3):178–184
[77] McLaughlin JF, Bjornson KF, Astley SJ, et al. Selective dorsal
rhizotomy: e cacy and safety in an investigator-masked
randomized clinical trial. Dev Med Child Neurol. 1998; 40
(4):220–232
[78] McLaughlin J, Bjornson K, Temkin N, et al. Selective dorsal
rhizotomy: meta-analysis of three randomized controlled
trials. Dev Med Child Neurol. 2002; 44(1):17–25
[79] Wright FV, Sheil EM, Drake JM, Wedge JH, Naumann S.
Evaluation of selective dorsal rhizotomy for the reduction of
spasticity in cerebral palsy: a randomized controlled tria.
Dev Med Child Neurol. 1998; 40(4):239–247
[80] Nordmark E, Josenby AL, Lagergren J, Andersson G,
Strömblad LG, Westbom L. Long-term outcomes five years
after selective dorsal rhizotomy. BMC Pediatr. 2008; 8:54
[81] Newberg NL, Gooch JL, Walker ML. Intraoperative
monitoring in selective dorsal rhizotomy. Pediatr
Neurosurg. 1991–1992; 17(3):124–127
[82] Albright AL, Turner M, Pattisapu JV. Best-practice surgical
techniques for intrathecal baclofen therapy. J Neurosurg.
2006; 104 suppl 4:233–239
[83] Kopell BH, Sala D, Doyle WK, Feldman DS, Wiso JH, Weiner
HL. Subfascial implantation of intrathecal baclofen pumps in
children: technical note. Neurosurgery. 2001; 49(3):753–
756, discussion 756–757
[84] Maarrawi J, Mertens P, Luaute J, et al. Long-term functional
results of selective peripheral neurotomy for the treatment
of spastic upper limb: prospective study in 31 patients. J
Neurosurg. 2006; 104(2):215–225
[85] Deletis V, Vodusek DB, Abbott R, Epstein FJ, Turndorf H.
Intraoperative monitoring of the dorsal sacral roots:
minimizing the risk of iatrogenic micturition disorders.
Neurosurgery. 1992; 30(1):72–75
[86] Fasano VA, Broggi G, Barolat-Romana G, Sguazzi A. Surgical
treatment of spasticity in cerebral palsy. Childs Brain. 1978;
4(5):289–305
[87] Peacock WJ, Arens LJ. Selective posterior rhizotomy for the
relief of spasticity in cerebral palsy. S Afr Med J. 1982; 62(4):
119–124
[88] Steinbok P, Schrag C. Complications after selective posterior
rhizotomy for spasticity in children with cerebral palsy.
Pediatr Neurosurg. 1998; 28(6):300–313
[89] Abbott R, Forem SL, Johann M. Selective posterior rhizotomy
for the treatment of spasticity: a review. Childs Nerv Syst.
1989; 5(6):337–346
[90] Abbott R, Johann-Murphy M, Shiminski-Maher T, et al.
Selective dorsal rhizotomy: outcome and complications in
treating spastic cerebral palsy. Neurosurgery. 1993; 33(5):
851–857, discussion 857
[91] Arens LJ, Peacock WJ, Peter J. Selective posterior rhizotomy:
a long-term follow-up study. Childs Nerv Syst. 1989; 5(3):
148–152
[92] Fasano VA, Broggi G, Zeme S, Lo Russo G, Sguazzi A. Long-
term results of posterior functional rhizotomy. Acta
Neurochir Suppl (Wien). 1980; 30:435–439
[93] Mooney JF, III, Millis MB. Spinal deformity after selective
dorsal rhizotomy in patients with cerebral palsy. Clin
Orthop Relat Res. 1999(364):48–52
[94] Turi M, Kalen V. The risk of spinal deformity after selective
dorsal rhizotomy. J Pediatr Orthop. 2000; 20(1):104–107
[95] Dudley RW, Parolin M, Gagnon B, et al. Long-term
functional benefits of selective dorsal rhizotomy for spastic
cerebral palsy. J Neurosurg Pediatr. 2013; 12(2):142–150
[96] O’Brien DF, Park TS, Puglisi JA, Collins DR, Leuthardt EC.
E ect of selective dorsal rhizotomy on need for orthopedic
surgery for spastic quadriplegic cerebral palsy: long-term
outcome analysis in relation to age. J Neurosurg. 2004; 101
suppl 1:59–63
[97] Watt JM, Robertson CM, Grace MG. Early prognosis for
ambulation of neonatal intensive care survivors with
cerebral palsy. Dev Med Child Neurol. 1989; 31(6):766–773
[98] Motta F, Buonaguro V, Stignani C. The use of intrathecal
baclofen pump implants in children and adolescents: safety
and complications in 200 consecutive cases. J Neurosurg.
2007; 107 suppl 1:32–35
[99] Murphy NA, Irwin MC, Ho C. Intrathecal baclofen therapy
in children with cerebral palsy: e cacy and complications.
Arch Phys Med Rehabil. 2002; 83(12):1721–1725
[100] Dickey MP, Rice M, Kinnett DG, et al. Infectious
complications of intrathecal baclofen pump devices in a
pediatric population. Pediatr Infect Dis J. 2013; 32(7):
715–722
[101] Co ey JR, Cahill D, Steers W, et al. Intrathecal baclofen for
intractable spasticity of spinal origin: results of a long-term
multicenter study. J Neurosurg. 1993; 78(2):226–232
[102] Penn RD. Intrathecal baclofen for spasticity of spinal origin:
seven years of experience. J Neurosurg. 1992; 77(2):
236–240
[103] Gardner B, Jamous A, Teddy P, et al. Intrathecal baclofen—a
multicentre clinical comparison of the Medtronics
Programmable, Cordis Secor and Constant Infusion Infusaid
drug delivery systems. Paraplegia. 1995; 33(10):551–554
[104] Taira T, Ueta T, Katayama Y, et al. Rate of complications
among the recipients of intrathecal baclofen pump in Japan:
a multicenter study. Neuromodulation. 2013; 16(3):266–
272, discussion 272
[105] Watve SV, Sivan M, Raza WA, Jamil FF. Management of acute
overdose or withdrawal state in intrathecal baclofen
therapy. Spinal Cord. 2012; 50(2):107–111
[106] Gooch JL, Oberg WA, Grams B, Ward LA, Walker ML.
Complications of intrathecal baclofen pumps in children.
Pediatr Neurosurg. 2003; 39(1):1–6
[107] Kofler M, Kronenberg MF, Rifici C, Saltuari L, Bauer G.
Epileptic seizures associated with intrathecal baclofen
application. Neurology. 1994; 44(1):25–27
Surgical Management of Pediatric Spasticity
379
[108] Deltombe T, Gustin T. Selective tibial neurotomy in the
treatment of spastic equinovarus foot in hemiplegic
patients: a 2-year longitudinal follow-up of 30 cases. Arch
Phys Med Rehabil. 2010; 91(7):1025–1030
[109] Kim JH, Lee JI, Kim MS, Kim SH. Long-term results of
microsurgical selective tibial neurotomy for spastic foot:
comparison of adult and child. J Korean Neurosurg Soc.
2010; 47(4):247–251
[110] Hesselgard K, Reinstrup P, Stromblad LG, Undén J, Romner B.
Selective dorsal rhizotomy and postoperative pain
management. Aworldwide survey. Pediatr Neurosurg. 2007;
43(2):107–112
[111] Anderson RCMC, Pinkus DW. Spastizcity—selective dorsal
rhizotomy. In: Jallo GI, ed. Controversies in Pediatric
Neurosurgery. 1st ed. New York, NY: Thieme; 2012
[112] Engsberg JR, Ross SA, Wagner JM, Park TS. Changes in hip
spasticity and strength following selective dorsal rhizotomy
and physical therapy for spastic cerebral palsy. Dev Med
Child Neurol. 2002; 44(4):220–226
[113] Richardson D. Physical therapy in spasticity. Eur J Neurol.
2002; 9 suppl 1:17–22, 53–61
[114] Tardieu C, Lespargot A, Tabary C, Bret MD. For how long
m ust the soleus m uscle be stretched each day to
prevent contracture? Dev Med Child Neurol. 1988; 30
(1):3–10
[115] Damiano DL. Activity, activity, activity: rethinking our
physical therapy approach to cerebral palsy. Phys Ther.
2006; 86(11):1534–1540
[116] Engsberg JR, Ross SA, Park TS. Changes in ankle spasticity
and strength following selective dorsal rhizotomy and
physical therapy for spastic cerebral palsy. J Neurosurg.
1999; 91(5):727–732
[117] Langerak NG, Lamberts RP, Fieggen AG, et al. A prospective
gait analysis study in patients with diplegic cerebral palsy
20 years after selective dorsal rhizotomy. J Neurosurg
Pediatr. 2008; 1(3):180–186
[118] Kan P, Gooch J, Amini A, et al. Surgical treatment of
spasticity in children: comparison of selective dorsal
rhizotomy and intrathecal baclofen pump implantation.
Childs Nerv Syst. 2008; 24(2):239–243
[119] Steinbok P. Outcomes after selective dorsal rhizotomy for
spastic cerebral palsy. Childs Nerv Syst. 2001; 17(1–2):1–18
[120] Mittal S, Farmer JP, Al-Atassi B, et al. Impact of selective
posterior rhizotomy on fine motor skills. Long-term results
using a validated evaluative measure. Pediatr Neurosurg.
2002; 36(3):133–141
[121] Albright AL, Gilmartin R, Swift D, Krach LE, Ivanhoe CB,
McLaughlin JF. Long-term intrathecal baclofen therapy for
severe spasticity of cerebral origin. J Neurosurg. 2003; 98
(2):291–295
[122] Gilmartin R, Bruce D, Storrs BB, et al. Intrathecal baclofen for
management of spastic cerebral palsy: multicenter trial. J
Child Neurol. 2000; 15(2):71–77
[123] Gerszten PC, Albright AL, Barry MJ. E ect on ambulation of
continuous intrathecal baclofen infusion. Pediatr Neurosurg.
1997; 27(1):40–44
[124] Francisco GE, Boake C. Improvement in walking speed in
poststroke spastic hemiplegia after intrathecal baclofen
therapy: a preliminary study. Arch Phys Med Rehabil. 2003;
84(8):1194–1199
[125] Bleyenheuft C, Filipetti P, Caldas C, Lejeune T. Experience
with external pump trial prior to implantation for
intrathecal baclofen in ambulatory patients with spastic
cerebral palsy. Neurophysiol Clin. 2007; 37(1):23–28
[126] Garland DE, Thompson R, Waters RL. Musculocutaneous
neurectomy for spastic elbow flexion in non-functional
upper extremities in adults. J Bone Joint Surg Am. 1980; 62
(1):108–112
Functional Disorders
380
IX
Section IX
Trauma
48 Neonatal Brachial Plexus
Injury
382
49 Pediatric Spine Trauma
390
50 Pediatric Peripheral Nervous
System Trauma
397
51 Management of Pediatric
Head Trauma
409
52 Abusive Head Trauma
423
48 Neonatal Brachial Plexus Injury
Jonathan Pindrik
48.1 Introduction
Neonatal brachial plexus injury (nBPI) occurs
within 0.4 to 4 newborns per 1,000 live births
annually.1,2,3 Shoulder dystocia indicates trapping
of the anterior shoulder below the pelvic rim dur-
ing delivery. While several obstetric maneuvers
ameliorate passage of the neonate through the
birth canal, mechanical or stretching forces jeop-
ardize the structural and functional integrity of
the brachial plexus. Temporary deficits that
resolve completely represent a neurapraxia. Other
injuries result in prolonged deficits that may
improve with surgical intervention and/or sponta-
neous neural regeneration. The severity of nBPI
typically relates to the number of nerves involved,
degree of structural damage and functional
impairment, and duration of neurological deficits.3
● Perinatal risk factors for nBPI: Fetal macrosomia,
prior delivery history of nBPI, multiparity, and
breech or complex deliveries (including those
requiring vacuum or forceps assistance).1,2
● Nearly one-third of infants with mild nBPI
exhibit incomplete recovery by 6 months of
age.1,2,3
● Over 80% of infants with severe nBPI exhibit
residual deficits by 6 months of age.3
● Neuropathological grading of nBPI severity is
based on the Sunderland classification: I—
neurapraxia; II—axonotmesis with myelin
damage; III—axonotmesis with endoneurial
damage; IV—axonotmesis with perineurial
disruption; V—neurotmesis with nerve
discontinuity.1,4
● Clinical grading system for nBPI severity:
Narakas’ classification3 ( Table 48.1).
● Less severe nBPIs show a greater propensity for
spontaneous neural regeneration and functional
recovery.3 More severe nBPIs typically result in
permanent deficits and require surgical
intervention.2
48.2 Anatomy
Originating from roots C5–T1, the brachial plexus
represents an organized network of peripheral
nerves ultimately innervating sensory derma-
tomes and muscle groups associated with the
upper extremity. Most nBPIs occur proximally at
the level of roots or trunks and a ect the upper
trunk (C5–C6) as in Erb–Duchenne palsy. The mid-
dle trunk (C7) also may sustain damage. Lower
trunk (C8–T1) injuries, consistent with Klumpke’s
palsy, rarely occur in isolation but may appear in
severe nBPI extending to the lower plexus.2 Mild
nBPIs involve stretch or traction injury with transi-
ent conduction impairment, while more severe
nBPIs may result in neuroma formation or nerve
root avulsion. A neuroma represents a focal collec-
tion of fibrosis and misdirected sprouting axons
along the course of an injured peripheral nerve.4
● The proximal portion of the brachial plexus
traverses the posterior cervical triangle,
bordered by the sternocleidomastoid, trapezius,
and clavicle.
● The hierarchical structure of the brachial plexus
from proximal to distal: Roots →trunks →
divisions →cords →branches ( Fig. 48.1).
Table 48.1 Narakas’ classification for neonatal brachial plexus injury (nBPI) severity
Narakas’ grade Description of injury
Comment
I
Involves upper trunk (C5, C6)
- Classic Erb–Duchenne palsy1,2
- Most common and least severe type1
- Most favorable prognosis1
II
Involves upper and middle trunks (C5, C6, C7)
- Less severe than type III or IV lesions
- Second most common type of nBPI1
III
Involves full plexus (C5–T1) with global impairment - Type III and IV lesions account for nearly 25%
of nBPIs
IV
Involves full plexus (C5–T1) with arm flaccidity and
possible Horner’s syndrome
- Most severe type of nBPI
- Suggests presence of preganglionic nerve root
avulsions1
Source: Data from Foad SL, Mehlman CT, Foad MB, Lippert WC. Prognosis following neonatal brachial plexus palsy: an
evidence-based review. J Child Orthop 2009;3(6):459–463.
382
● The nerve roots of the brachial plexus travel
between the anterior and middle scalene muscles
to form the upper, middle, and lower trunks.
● From their respective trunks, divisions and cords
run inferolaterally between the clavicle and first
thoracic rib into the axilla.
● The lateral, medial, and posterior cords are
named anatomically with respect to the axillary
artery.
● Inferior to the clavicle, the cords pass deep to the
pectoralis major and minor muscles.
48.3 Examination
Physical examination of infants with nBPI evalu-
ates passive and active movement and any asym-
metries or deformities associated with the upper
extremity. Examination involves observation of
spontaneous activity and intentional reaching or
grasping of presented objects.1 Most nBPIs involve
deficits of shoulder external rotation or abduction
and elbow flexion. Middle trunk injury addition-
ally impairs extension about the elbow, wrist, and/
or fingers. Lower trunk involvement causes deficits
in hand or finger movement.
● Assessing the passive range of motion about the
shoulder and elbow may reveal contractures.
● Palpation of the pectoralis major, latissimus
dorsi, and teres major muscles may reveal
tightness.1
● Glenohumeral subluxation or instability should
be assessed visually and tactilely during rest and
passive range of motion exercises.1
● Active movement about the shoulder, elbow,
wrist, forearm, and fingers should be thoroughly
assessed without and with gravity. Findings can
be graded and recorded using the Toronto
Obstetric Brachial Plexus Active Movement Scale
(AMS).
● Examination of other systems may reveal
neurological deficits. For instance,
approximation of the diaphragmatic height or
chest radiography may reveal hemidiaphragm
elevation due to phrenic nerve dysfunction.
Fig. 48.1 Anatomical diagram of the brachial plexus. (Reproduced with permission from Figure 1–44. Brachial Plexus.
Page 80. Comprehensive Neurosurgery Board Review by Citow, Macdonald, Kraig, Wollmann. Thieme 2000.)
Neonatal Brachial Plexus Injury
383
● Lesions extending inferiorly to the lower trunk
may cause an incomplete Horner’s syndrome
with ptosis and myosis. This often suggests
preganglionic nerve root avulsion of C8 and/or
T1.1
48.4 Nonsurgical Management
Initial patient evaluation within 2 weeks of deliv-
ery helps establish a neurological baseline for later
comparison in nBPI. The next follow-up appoint-
ment should occur at 3 months of age. Depending
on the severity of nBPI and management strategy,
reevaluation may occur at age 6 to 9 months or
sooner. These serial examinations help track the
progression of neurological deficits and functional
impairment. Patients that exhibit adequate func-
tional recovery (at least partial antigravity
strength) in motion about the shoulder, elbow,
and/or hand may be managed nonoperatively.1
Clinic visits provide the opportunity to link the
patient and family with specialists trained in phys-
iotherapy or physical medicine and rehabilitation.
Physiotherapy exercises focus on passive range of
motion and stimulation to encourage activity
of the a ected extremity. Furthermore, parents or
caretakers may be coached regarding appropriate
positioning strategies and activities to mobilize
the a ected extremity. Supervised home therapy
may help reduce contracture formation about the
shoulder or elbow, promote shoulder stability, and
help prevent neglect of the paretic limb.1,2 Physio-
therapy and rehabilitative care also represent
important adjuncts to operative management.
48.5 Surgical Indications
Serial evaluations and monitoring of nBPI allow
su cient time to observe spontaneous neural
regeneration.1 Inadequate functional recovery in
shoulder external rotation or abduction, elbow
flexion, and/or hand movement by age 3 months
prompts surgical consideration during the 3- to 6-
month age range.1,2,5 Some peripheral nerve sur-
geons prefer surgical intervention at 9 months of
age to allow longer observation periods for sponta-
neous recovery.1 When nerve root avulsions are
present, surgical intervention should occur at the
earliest time point.
● Inadequate performance on objective measures
such as the Toronto Obstetric Brachial Plexus
Active Movement Scale (AMS) and the Cookie
test may corroborate surgical decision making.
● The presence of Horner’s syndrome on follow-up
examination at age 3 months indicates severe
nBPI likely spanning the full plexus. Extensive
nBPIs usually require early surgical intervention.
● Additional diagnostic studies help investigate
the severity of injury and corroborate surgical
decision making. Cervical spine magnetic
resonance imaging (MRI) may reveal
pseudomeningoceles suggesting nerve root
avulsion.
● Other ancillary studies include
electromyography and nerve conduction studies,
performed at or beyond 3 months of age.2,4
These studies help identify the presence of
regenerating motor units and conducting action
potentials.
48.6 Surgical Technique
Most operative explorations and repairs of nBPI
require a supraclavicular approach. Extension of
the traumatic injury or neuroma along the divi-
sions and cords may require the addition of an
infraclavicular approach. Following exposure of
normal anatomy, the injured elements of the bra-
chial plexus can be identified through direct visu-
alization and nerve stimulation. Depending on the
extent of injury and function of donor nerves, vari-
ous methods of repair may be employed. Di erent
types of peripheral nerve repair include neurolysis,
neuroma resection and grafting, and nerve transfers
(with or without bridging grafts). The goals of sur-
gery revolve around promoting neural regeneration
and muscular reinnervation to improve elbow flex-
ion and shoulder stability, abduction, and external
rotation. Additional approaches target hand and fin-
ger functional recovery. For all nBPI explorations
and repairs, anesthetic paralytic agents should be
avoided.
● Patient position: Supine, head rotated
contralaterally, with a rolled sheet or bump
under the upper torso to elevate the
supraclavicular region.
● Special lucent drapes or sterile preparation of
the a ected extremity within the surgical field
allow intraoperative nerve stimulation and
observation of muscular contractions.
● One or both lower extremities should be sterilely
prepared from the popliteal fossa to lateral
malleolus if surgical planning involves sural
nerve harvesting.
● Skin incision for supraclavicular approach:
Parallel to and one to two finger-breadths above
Trauma
384
the clavicle, extending laterally toward the
anterior border of the trapezius and medially
along the posterior border of the
sternocleidomastoid (as needed).6
● Skin incision for infraclavicular approach:
Vertically oblique line along the deltopectoral
groove, curving medially toward the clavicle.
● Relevant anatomical landmarks: See